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The neuropeptide, orphanin FQ/nociceptin (OFQ/N or simply, nociceptin), is expressed in
both neuronal and non-neuronal tissue, including the immune system. In the brain, OFQ/N
has been investigated in relation to stress, anxiety, learning and memory, and addiction.
More recently, it has also been found that OFQ/N inﬂuences glial cell functions, including
oligodendrocytes, astrocytes, and microglial cells. However, this latter research is relatively
small, but potentially important, when observations regarding the relationship of OFQ/N to
stress and emotional functions is taken into consideration and integrated with the growing
evidence for its involvement in cells that mediate inﬂammatory events. This review will
ﬁrst provide an overview and understanding of how OFQ/N has been implicated in the
HPA axis response to stress, followed by an understanding of its inﬂuence on natural and
learned anxiety-like behavior. What emerges from an examination of the literature is a
neuropeptide that appears to counteract anxiogenic inﬂuences, but paradoxically, without
attenuating HPA axis responses generated in response to stress. Studies utilized both
central administration of OFQ/N, which was shown to activate the HPA axis, as well as
antagonism of NOP-R, the OFQ/N receptor. In contrast, antagonist or transgenic OFQ/N
or NOP-R knockout studies, showed augmentation of HPA axis responses to stress,
suggesting that OFQ/N may be needed to control the magnitude of the HPA axis response
to stress. Investigations of behavior in standard exploratory tests of anxiogenic behavior
(eg., elevated plus maze) or learned fear responses have suggested that OFQ/N is needed
to attenuate fear or anxiety-like behavior. However, some discrepant observations, in
particular, those that involve appetitive behaviors, suggest a failure of NOP-R deletion to
increase anxiety. However, it is also suggested that OFQ/N may operate in an anxiolytic
manner when initial anxiogenic triggers (eg., the neuropeptide CRH) are initiated. Finally,
the regulatory functions of OFQ/N in relation to emotion-related behaviors may serve to
counteract potential neuroinﬂammatory events in the brain. This appears to be evident
within the glial cell environment of the brain, since OFQ/N has been shown to reduce the
production of proinﬂammatory cellular and cytokine events. Given that bothOFQ/N and glial
cells are activated in response to stress, it is possible that there is a possible convergence
of these two systems that has important repercussions for behavior and neuroplasticity.
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INTRODUCTION
Orphanin FQ/nociceptin (OFQ/N) is a heptadecapeptide most
closely related to the endogenous kappa opioid peptide (KOP)
dynorphin A (Meunier et al., 1995; Reinscheid et al., 1995).
The peptide is referred interchangeably to either OFQ/N
or nociceptin, due to its known hyperalgesic effects (Rein-
scheid et al., 1995). Early studies surrounding the isolation
of this opioid-like neuropeptide revealed that OFQ/N lacks
afﬁnity for traditional opioid receptors (Bunzow et al., 1994;
Mollereau et al., 1994; Reinscheid et al., 1996). Eventually it
was shown that OFQ/N binds selectively to a G protein cou-
pled receptor, the nociceptin opioid-like peptide (NOP) recep-
tor (also known as ORL-1 or opioid-like orphan receptor
1), which resembles the classical opioid receptors in struc-
ture but does not bind opioid ligands (Bunzow et al., 1994;
Fukuda et al., 1994; Mollereau et al., 1994; Wick et al., 1994).
At the cellular level, activation of the NOP receptor (NOP-R)
exerts inhibitory effects as it is negatively coupled to adeny-
lyl cyclase (Mollereau et al., 1994; Wang et al., 1994), stimu-
lates K+ conductance (Hawes et al., 2000) and inhibits high-
voltage activated (HVA) N-type Ca2+ channels (Altier and
Zamponi, 2008). As a result, OFQ/N binding to NOP-R
reduces neuronal excitability and inhibits neurotransmitter release
(Schlicker and Morari, 2000).
The OFQ/N peptide is derived through enzymatic cleavage
from a larger precursor peptide, that also liberates other biolog-
ically active peptides (see Figure 1; Meunier et al., 1995; Okuda-
Ashitaka et al., 1998; Reinscheid et al., 2000; Mogil and Pasternak,
2001). In this way, the nociceptin precursor, preproOFQ/N
(ppOFQ/N), is similar to proopiomelanocortin (POMC), the
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FIGURE 1 | Amino acid sequences for mouse (187 aa) and rat (181 aa)
nociceptin precursors (ppOFQ/N).The signal peptide is labeled and shown
in italics. Proteolytic cleavage sites are shown in red, bold font. Enzymatic
cleavage may occur at multiple sites along the ppOFQ/N peptide generating
three biologically active neuropeptides; OrphaninFQ/Nociceptin (blue),
Nocistatin (orange) and NocII/OFQII (red; Mollereau et al., 1996).
precursor to several unrelated bioactive peptides (Meunier et al.,
1995). More speciﬁcally, ppOFQ/N codes for two additional neu-
ropeptides, nocistatin and NocII/OFQII, that lie immediately
upstreamanddownstream, respectively, of OFQ/N(Meunier et al.,
1995; Okuda-Ashitaka et al., 1998; Reinscheid et al., 2000). Less
is known regarding the functional role of these neuropeptides,
although there is evidence to suggest that nocistatin exerts bio-
logical effects opposite to those of OFQ/N (Okuda-Ashitaka et al.,
1998; Gavioli et al., 2002).
High sequence homology between OFQ/N, NOP-R and com-
ponents of the opioid superfamily prompted initial investigations
into the role of OFQ/N in nociception (Meunier et al., 1995; Rein-
scheid et al., 1995; Rossi et al., 1998). Early ﬁndings revealed the
relationship between nociceptin signaling and pain transmission
to be complex as OFQ/N produced hyperalgesia when adminis-
tered supraspinally (Mollereau et al., 1994; Reinscheid et al., 1995)
and analgesia when administered at spinal sites (Rossi et al., 1998).
Further investigation of the OFQ/N system revealed that both
OFQ/N and its receptor are prominently expressed in stress-
sensitive limbic and limbic-associated brain structures involved
in processing emotionally relevant stimuli (Bunzow et al., 1994;
Nothacker et al., 1996; Neal et al., 1999a,b; Pampusch et al., 2000).
Since this suggested a potential role for OFQ/N in behaviors other
than nociception, a good deal of effort has been directed to deter-
mining the role of OFQ/N in stress-related endocrine functions
and behavior. Moreover, several reviews have highlighted the
importance of OFQ/N in the modulation of reward, addiction
and learning (Noda et al., 2000; Koob, 2008; Kuzmin et al., 2009;
Zaveri, 2011).
In the current review, focus will be placed on the ability
of OFQ/N to modulate anxiety-related behaviors and stress-
induced neuroendocrine responses. In addition, the emerging
role of OFQ/N in immune and/or inﬂammatory processes will
be considered. There is considerable evidence that OFQ/N and
NOP-R are expressed in endocrine (i.e., adrenal gland), and
lymphoid organs and cells (e.g., blood leukocytes), including
those considered to constitute “immune-like” functions in the
CNS (Wang et al., 1994; Halford et al., 1995; Lachowicz et al.,
1995; Nothacker et al., 1996; Peluso et al., 1998; Pampusch et al.,
2000; Finley et al., 2008). Importantly, broad yet restricted expres-
sion of OFQ/N and NOP-R throughout the CNS and periphery
suggests a modulatory role for the nociceptin system in regula-
tion of emotional states, cognitive processes, and neuroendocrine
and immune functions (Halford et al., 1995; Mamiya et al., 1998;
Nabeshima et al., 1999; Devine et al., 2001; Leggett et al., 2009a).
Accordingly, this paper will address the large but controversial
literature concerning the role of OFQ/N inmodulating physiolog-
ical and behavioral responses to stress. In addition, the putative
role of the nociceptin system in regulating neuroinﬂammatory
processes will be discussed. This research is potentially impor-
tant, given the relationship of OFQ/N to stress and emotional
functions, and the increasing relevance of this to inﬂammatory
events.
ORPHANIN FQ/NOCICEPTIN AND RESPONSES TO
PSYCHOGENIC STRESS
Stress as a physiological state originates from both systemic and
psychogenic origins impacting nervous, endocrine and immune
system functions. Of particular interest is the hypothalamic-
pituitary-adrenal (HPA) axis, a major branch of the neuroen-
docrine system and the principle endocrine component of the
stress response. Exposure to stress, both physical and psycho-
logical, activates the HPA axis, triggering a neuroendocrine
cascade that culminates in the release of glucocorticoids [corti-
sol in humans and corticosterone (CORT) in rodents]. Brieﬂy,
stressor exposure activates neurosecretory cells of the paraven-
tricular nucleus (PVN) of the hypothalamus, which secrete
corticotropin-releasing hormone (CRH; also known as CRF) into
the hypophyseal portal circulation. Once in the anterior pitu-
itary, CRH stimulates CRH receptor I (CRH-RI) and induces
the release of adrenocorticotropic hormone (ACTH), which is
released into the systemic circulation, and subsequently stimu-
lates the secretion of glucocorticoids from the adrenal cortex.
A variety of stimuli can serve as stressors to the activation of
the HPA axis, including psychogenic, physical and immunologic
stressors. In most cases, such stressors engage higher level neu-
ral processes mediated by limbic forebrain structures, such as
the amygdala, bed nucleus of the stria terminalis (BNST) and
medial prefrontal cortex (mPFC), all of which either directly
or indirectly form connections that ultimately impact the PVN
(Ulrich-Lai and Herman, 2009).
The stress-induced elevationof CORTserves tomobilize energy
stores and increase arousal. In this way, glucocorticoids are ben-
eﬁcial for short-term survival as they prepare animals to cope
with real or perceived threats to homeostasis. However, pro-
longed exposure to glucocorticoids can, among other things,
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suppress normal immune function and impair cognition. For
this reason, glucocorticoid release following stressor exposure is
tightly regulated and involves integration of complex feed-forward
and feedback signals at the level of the brain. Notably, circulat-
ing glucocorticoids provide feedback inhibition that is mediated,
in part, by limbic-associated structures (Jankord and Herman,
2008; Ulrich-Lai and Herman, 2009). Speciﬁcally, while there are
multiple levels of glucocorticoid feedback, binding of CORT to
glucocorticoid receptors (GR) in the hippocampus and mPFC
contributes to the inhibitory regulation of HPA axis activation
(Herman et al., 2012).
Accumulating evidence strongly implicates the nociceptin sys-
tem in regulation of the stress response in general, and emerging
data suggest that OFQ/N may contribute to feed-forward reg-
ulation of the HPA axis speciﬁcally. Therefore, evidence is
reviewed regarding the involvement of endogenous OFQ/N in the
regulation of the HPA axis response to acute psychogenic stress. A
summary of these ﬁndings is provided in Tables 1 and 2, as well as
Figure 2.
OFQ/N AND THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
Studies concerning the role of the nociceptin system in regulation
of the HPA axis consistently demonstrate that central administra-
tion of OFQ/N elevates circulating ACTH and plasma CORT in
unstressed rats (Devine et al., 2001; Nicholson et al., 2002; Leggett
et al., 2006). Moreover, OFQ/N enhances endocrine responses
during neophobic tests of anxiety such as exposure to the open
ﬁeld (OF; Devine et al., 2001; Fernandez et al., 2004; Green et al.,
2007) and elevated plus maze (EPM; Vitale et al., 2006). Such
ﬁndings implicate OFQ/N in feed-forward regulation of the HPA
axis, and further suggest that nociceptin signaling may mediate or
contribute to the HPA axis response to psychogenic stress.
Table 1 | Effects of manipulating the nociceptin system on the hypothalamic-pituitary-adrenal (HPA) axis response in stressed and non-stressed
animals.
OFQ/N manipulation under resting conditions Neuroendocrine effect
Manipulation Species Dose (route of administration) Hypothalamus Pituitary Plasma Reference
OFQ/N infusion Rats 0.10–1.0 nmole (icv) N/A N/A ↑ ACTH
↑ CORT
Devine et al. (2001)
Rats 2.55 nmole (icv) N/A N/A ↑ ACTH Nicholson et al. (2002)
Rats 0.10–10 μg/rat (icv) ↑ CRH mRNA (PVN) ↑ POMC
mRNA
↑ ACTH
↑ CORT
Leggett et al. (2006)
Rats 3 nmole (icv) ↑ # of c-Fos+ cells
(PVN, SON)
N/A N/A Olszewski et al. (2000)
JTC-801 Rats 0.05 mg/kg (iv) N/A N/A ↑ CORT Delaney et al. (2012)
1 μg/rat (icv) ↑ # of c-Fos+ cells
(PVN)
N/A N/A
OFQ/N−/− knockout Mice N/A N/A N/A ↑ CORT (basal
vs OFQ/N+/+)
Koster et al. (1999)
OFQ/N manipulation during stressor exposure
Manipulation Species Dose (route of administration)/
Type of stress
Hypothalamus Pituitary Plasma Author
OFQ/N + psychogenic
stress
Rats 1.0 nmole (icv)/open ﬁeld test N/A N/A ↑↑ ACTH
→ CORT
Devine et al. (2001)
Rats 0.01–1.0 nmole (icv)/open ﬁeld test N/A N/A ↑↑ CORT Fernandez et al. (2004)
Rats 0.01–1.0 nmole (icv)/open ﬁeld test N/A N/A ↑↑ CORT Green et al. (2007)
Rats 0.5–1.5 nmole (icv)/elevated plus maze N/A N/A ↑↑ CORT Vitale et al. (2006)
UFP-101 + psychogenic
stress
Rats 1 μg/rat (icv)/Restraint Ø CRH mRNA (PVN) Ø POMC
mRNA
↑ CORT Leggett et al. (2007)
OFQ/N−/− knockout +
psychogenic stress
Mice Exposure to Elevated plus maze N/A N/A ↑↑ CORT (vs
OFQ/N+/+)
Koster et al. (1999)
OFQ/N, orphaninFQ/nociception; NOP-R, nociceptin receptor; OFQ/N−/−, nociceptin deﬁcient (knockout); OFQ/N+/+, nociceptin intact (wildtype); JTC-801, NOP-
R antagonist; UFP-101, NOP-R antagonist; icv, intracerebroventricular; iv, intravenous; CRH, corticotropin releasing hormone; PVN, paraventricular nucleus; SON,
supraoptic nucleus; POMC, proopiomelanocortin; ACTH, adrenocorticotropic hormone; CORT, corticosterone; N/A, not applicable or effects not addressed in cited
study; Ø, no effect; ↑, increase above baseline/corresponding control; ↑↑, enhanced elevation above corresponding control; →, prolonged elevation of stress-induced
response.
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Table 2 | Putative neural substrates mediating the stimulatory effects of OFQ/N on the hypothalamic-pituitary-adrenal (HPA) axis.
Region Species Supporting evidence Reference
Hypothalamus Rats OFQ/N (0.10–1 μg, icv) ↑ CRH mRNA expression (PVN)
OFQ/N (3 nmole, icv) ↑ c-Fosimmunoreactivity (PVN)
Olszewski et al. (2000);
Leggett et al. (2006)
Pituitary Rats OFQ/N (0.10–10 μg, icv) ↑ POMC mRNA Leggett et al. (2006)
Hippocampus Rats Restraint stress ↑ OFQ/N release (CA1, CA3, DG) Nativio et al. (2012)
BNST Rats Restraint stress ↓ OFQ/N content in forebrain region containing BNST (increased
utilization?)
Devine et al. (2003)
Rats Intra-BNST injections (1.0 nmole) of OFQ/N ↑ circulating CORT Green et al. (2007)
Rats OFQ/N (75 nM) inhibits neuronal ﬁring in the BNST (in vitro) Dawe et al. (2010)
SCN Rats OFQ/N (10–1000 nM) inhibited excitatory synaptic transmission in the SCN evoked
by optic nerve stimulation (via presynaptic mechanisms)
OFQ/N (3–1000 nM) inhibited GABA release from SCN neurons (via presynaptic
mechanisms)
Gompf et al. (2005)
Rats OFQ/N (0.5 and 10 nM, icv) inhibited light-induced c-Fos expression in the SCN Sugino et al. (2006)
Abbreviations used (those not already indicated inTable 1): CA1, cornuAmmonis 1 region; CA3, cornuAmmonis 3 region; DG, dentate gyrus; BNST, bed nucleus of
striaterminalis; SCN, suprachiasmatic nucleus; GABA, γ-aminobutyric acid; ↑, increased expression; ↓, decreased expression.
FIGURE 2 | Feed-forward effects of OFQ/N on the hypothalamic-
pituitary-adrenal (HPA) axis response to stress. The stimulatory effects
of OFQ/N on the HPA axis are mediated through disinhibitory signaling (*)
in multiple brain regions. Following activation of the HPA axis, CORT is
released into circulation. At the level of the hippocampus, CORT binds to
and stimulates GR which provides negative feedback control over HPA
axis activity (red solid arrows). Binding of CORT to GR also induces the
expression of OFQ/N, which binds to NOPr in the hippocampus and
inhibits glutamatergic transmission (blue solid arrows) thereby removing
trans-synaptic inhibition of the PVN. Nociceptin signaling also inhibits
GABAergic outputs (red dashed arrows) from the BNST to the PVN,
which attenuates the restraining inﬂuence of the BNST on PVN activity.
Finally, nociceptin may also exert feed-forward effects on the HPA axis by
suppressing inhibitory output from the SCN to the PVN. In this way,
OFQ/N stimulates PVN neurons indirectly to produce CRH, which induces
the expression of POMC and stimulates the release of ACTH. Collectively,
these changes prolong or enhance the HPA axis response to stress.
[Note: although depicted in this schematic for completeness, OFQ/N does
not modulate amygdalar-outputs (CeA, central amygdala; MeA, medial
amygdala; BLA, basolateral amygdala) to the PVN].
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 173 | 4
“fncel-07-00173” — 2013/10/4 — 21:26 — page 5 — #5
Mallimo and Kusnecov Orphanin FQ/nociceptin, stress, neuroinﬂammation
In apparent contrast to these ﬁndings, mice lacking the noci-
ceptin gene (OFQ/N−/−) exhibit elevated basal and post-stress
levels of plasma CORT relative to wildtype mice, suggesting that
OFQ/N serves to dampen HPA axis output (Koster et al., 1999).
While seemingly at odds with one another, the discrepant ﬁndings
of Koster et al. (1999) and others (Devine et al., 2001; Nicholson
et al., 2002; Fernandez et al., 2004; Leggett et al., 2006; Vitale et al.,
2006; Green et al., 2007) could be ascribed to several factors. First,
enhancedHPAaxis activity inOFQ/N−/− micemaybedue todeﬁ-
cient OFQ/N signaling during key developmental processes rather
than due to a lack of OFQ/N per se. In fact, ppOFQ/N and NOP-R
mRNA transcripts are highly expressed during early, embryonic
development, raising the possibility that OFQ/N signaling con-
tributes to normal neuronal development (Ikeda et al., 1998). Of
additional concern is that the ppOFQ/N gene, that was disrupted
by Koster et al. (1999), encodes additional peptides that exert bio-
logical effects opposite to those of OFQ/N (Okuda-Ashitaka et al.,
1998). Accordingly, the ﬁndings of Koster et al. (1999) might not
be directly attributable to a loss of OFQ/N-NOP-R signaling.
These concerns notwithstanding, pharmacological blockade
of NOP-R was shown to enhance stress-induced activation of
the HPA axis (Leggett et al., 2007). Speciﬁcally, intracerebroven-
tricular (icv) administration of the peptide NOP-R antagonist,
UFP-101, enhanced and prolonged, respectively, ACTH and
CORT responses to acute restraint (Leggett et al., 2007). This
supports the notion that nociceptin signaling exerts a restrain-
ing effect on the HPA response to stressors (Koster et al., 1999),
although under certain conditions UFP-101 acts as a partial ago-
nist at the NOP-R receptor, potentially mimicking the effects of
OFQ/N (Mahmoud et al., 2010). For example, under conditions
in which NOP-R was highly expressed and constitutively active,
UFP-101 inhibited Ca2+ currents in cultured, stellate ganglion
neurons in a manner similar to that of OFQ/N (Mahmoud et al.,
2010). On the other hand, UFP-101 blocked OFQ/N-mediated
Ca2+ current inhibition in control cells expressing NOP-R at
physiological levels (Mahmoud et al., 2010). Therefore, given
its mixed pharmacological proﬁle, it is uncertain whether in
Leggett et al.’s (2007) study, UFP-101 enhanced restraint-stress
induced activation of the HPA axis via partial agonist effects at
NOP-R.
In a more recent study, the HPA modulatory effects of a dif-
ferent non-peptide NOP-R antagonist, JTC-801, were examined
during exposure to an acute restraint stressor (Delaney et al.,
2012). Although it did not further increase stress-induced lev-
els of CORT, intravenous (iv) JTC-801 elevated plasma CORT
in unstressed rats. This suggested that nociceptin tonically reg-
ulates, in an inhibitory fashion, basal activity of the HPA axis
(Delaney et al., 2012), which contrasted with other evidence that
UFP-101 did not alter basal HPA axis activity (Leggett et al., 2007).
Once again, however, and like other NOP-R antagonists, JTC-801
exhibits a complex pharmacological proﬁle including antagonist
and inverse agonist actions (Mahmoud et al., 2010), and allosteric
regulation (Sestili et al., 2004; Del Giudice et al., 2011). There-
fore, other experimental factors could have inﬂuenced the effect
of JTC-801 on the HPA axis including route of drug administra-
tion, dose-response characteristics, and the selectivity proﬁle of
JTC-801 at NOP-R (Delaney et al., 2012).
It seems, therefore, that pharmacological attempts to deter-
mine the role of OFQ/N in the HPA axis response to stress have
been hampered by poorly selective NOP-R antagonists. Moreover,
the lack of correspondence in methodology renders the results
of these studies difﬁcult to reconcile. Although this has created
some uncertainty regarding whether OFQ/N is necessary for acti-
vation or inhibition of the HPA axis, it has not deterred efforts
to identify the neural substrate(s) and signaling mechanism(s)
that might underlie OFQ/N involvement in HPA axis regulation.
One possibility is that nociceptin contributes to the synthesis and
release of other major hormones or peptides that exert excita-
tory effects on the HPA axis. In fact, OFQ/N-induced activation
of the HPA axis is paralleled by up-regulation of CRH mRNA in
the PVN of the hypothalamus and increased expression of POMC
mRNA in the pituitary (Leggett et al., 2006). Moreover, icv admin-
istration of OFQ/N reportedly increased Fos protein expression
in the PVN (Olszewski et al., 2000). However, given that OFQ/N
binding to NOP-R reduces neuronal excitability, inhibiting both
glutamate and GABA release (Meis and Pape, 2001; Bianchi et al.,
2004; Roberto and Siggins, 2006; Cruz et al., 2012), it is likely that
activation of PVN neurons in response to OFQ/N occurs through
indirect mechanisms.
It has been suggested that OFQ/N may drive HPA axis out-
put by disrupting limbic feedback to the hypothalamus (Devine
et al., 2001; Leggett et al., 2006; see Figure 2). It is recognized that
the hippocampus expresses high levels of GR, and this serves as
a major source of glucocorticoid-mediated feedback control over
HPA axis output (Sapolsky et al., 1983). The hippocampal GR
are bound by circulating CORT, one effect of which is enhance-
ment of glutamatergic transmission (Jankord and Herman, 2008;
Ulrich-Lai and Herman, 2009). This can result in trans-synaptic
excitation of an inhibitory relay in the BNST thatmaintains and/or
augments inhibition of the PVN (Jankord and Herman, 2008).
This normal state of affairs, however, might be disrupted by
OFQ/N (see Figure 2). Exposure of rats to acute restraint increases
OFQ/N release in the hippocampus in an adrenal-dependent
manner, and mimicked by CORT injection, suggesting that gluco-
corticoids are necessary for stress-induced hippocampal OFQ/N
release (Nativio et al., 2012). However, it is not known whether
this glucocorticoid-dependent hippocampal OFQ/N release sub-
sequent to stressor exposure prolongs or enhances HPA axis
activity.
Alternatively, there is evidence that OFQ/N release in the BNST
may play a role in modulating the HPA axis. As mentioned, the
neural circuitry for regulation of the HPA axis includes the BNST,
which contains GABAergic cells that send afferents to the PVN
and inhibit HPA responses to stress (Ulrich-Lai and Herman,
2009). Acute restraint stress was reported to reduce OFQ/N con-
tent in gross dissections of the basal forebrain region containing
the BNST, and this was argued to reﬂect increased release and
utilization of OFQ/N (Devine et al., 2003). Importantly, OFQ/N
neurotransmission and stimulation of NOP-R in the BNST is
thought to reduce GABAergic input to the PVN, which ultimately
would prolong activation of the HPA axis and stress-induced ele-
vations of CORT. Consistent with this hypothesis, OFQ/N elicits
strong inhibition of BNST neuronal ﬁring in vitro (Dawe et al.,
2010). Moreover, unilateral, intra-BNST infusion of OFQ/N in
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rats dose-dependently enhanced the CORT response to mild psy-
chogenic stress (exposure to an OF; Green et al., 2007). At the very
least, therefore, it could be argued that OFQ/N-mediated signaling
in the BNST has signiﬁcant consequences on HPA axis functions
precipitated by stressors; whether this also involves hippocampal
recruitment as suggested above remains to be determined.
The amygdala has also received attention as a potential medi-
ator of OFQ/N effects on the HPA axis (Green et al., 2007). A
heterogeneous structure comprised of many nuclei, the amygdala
is differentially recruited by systemic and psychogenic stressors,
which affects the PVN indirectly through synaptic inputs in the
BNST (Ulrich-Lai and Herman, 2009). The two major output
nuclei of the amygdala (central and medial amygdala; CeA and
MeA) contain inhibitory projection neurons that synapse onto
GABAergic cell groups in the BNST (Ulrich-Lai and Herman,
2009). Therefore, by means of a disinhibitory process, activation
of the CeA and/or MeA results in excitation rather than inhibition
of the PVN. Interestingly, injections of OFQ/N into the amygdala
did not alter the CORT response to a mild, psychogenic stres-
sor (Green et al., 2007), in spite of other evidence that (1) social
defeat stress induced NOP-R mRNA expression in the CeA and
basomedial (BMA) nuclei of the amygdala (Green and Devine,
2009), (2) acute restraint stress reduced ppOFQ/NmRNA expres-
sion in the CeA (Delaney et al., 2012), and (3) icv administration
of OFQ/N induced Fos protein expression in the CeA (Olszewski
et al., 2000). Based on such evidence, it is not unlikely that OFQ/N
signaling occurs in the amygdala, and can increase anxiety-like
behavior (Green et al., 2007). However, such intra-amygdalar
behavioral effects are likely to be dissociated from the neuroen-
docrine effects of OFQ/N, which most likely engage alternative
pathways.
Finally, it has been suggested that the stimulatory effects of
OFQ/N on glucocorticoid release arise from modulation of cir-
cadian inputs to the HPA axis (Devine et al., 2001; Leggett et al.,
2007). In rodents, blood CORT concentrations are lowest dur-
ing the light or diurnal phase of the circadian cycle, and peak in
the nocturnal phase, when rodents display high levels of activity,
including increased food and water intake. Similarly, CORT-
mediated negative feedback regulation of ACTH varies across
the circadian light/dark cycle. For example, exposure to stress
during the nadir or low phase of the CORT circadian rhythm
induces an ACTH response of greater magnitude than during
the peak phase. A critical structure in the regulation of circadian
rhythms is the suprachiasmatic nucleus (SCN) of the hypotha-
lamus, which relays photic information from the retina to the
PVN. Interestingly, NOP-R is prominently expressed in the SCN,
and OFQ/N has been shown to alter the activity of SCN neu-
rons both in vitro (Gompf et al., 2005) and in vivo (Sugino et al.,
2006). For example, icv administration of OFQ/N suppressed
light-induced c-Fos expression in the SCN of rats (Sugino et al.,
2006), while OFQ/N inhibited both excitatory and inhibitory neu-
rotransmission in SCN neurons (Gompf et al., 2005). In view of
these ﬁndings, it has been hypothesized that OFQ/Nmight stimu-
late the HPA axis and enhance endocrine responses to acute stress
by altering circadian input to the PVN across the light/dark cycle
(Devine et al., 2001; Leggett et al., 2007). Although it is also likely
that OFQ/N-dependent modulation of the HPA axis response to
acute psychogenic stress occurs through additive actions in multi-
ple limbic and extra-limbic sites (Devine et al., 2001; Green et al.,
2007).
In summary, there is consistent evidence that OFQ/N is
involved in the activation of the HPA axis. What is not clear at
present is the precise mechanism by which this occurs. One fac-
tor that has not been fully investigated with regard to the HPA
axis is the role of neurotransmitter systems regulated by OFQ/N.
For example, there is evidence to suggest that OFQ/N exerts an
inhibitory effect on the release of acetylcholine (ACh) in cor-
tical, hippocampal and striatal brain regions (Itoh et al., 1999;
Cavallini et al., 2003; Uezu et al., 2005). Cholinergic stimulatory
effects on the HPA axis have long been recognized (Matta et al.,
1998; Rhodes et al., 2001), and it might be expected that if OFQ/N
exerts an inhibitory effect on ACh, this could be one mechanism
by which an inhibition of the HPA axis is maintained. Indeed,
the elevated and/or prolonged HPA axis responses observed in the
absence of OFQ/N or loss of NOP-R signaling (Koster et al., 1999;
Mallimo et al., 2010), ﬁt this particular explanatory scheme. How-
ever, whether modulation of the cholinergic system is involved,
remains to be determined.
OFQ/N AND REGULATION OF ANXIETY STATES
Anxiety as a mental state is characterized by heightened arousal,
hypervigilance and the expression of defensive behaviors (e.g.,
escape or avoidance). Anxiety-responses are evoked in anticipa-
tion of threat and are accompanied by autonomic and endocrine
activation. Collectively, these physiological and behavioral reac-
tions are thought to be adaptive and prepare an individual to cope
with unexpected or unavoidable situations. Although there is no
shortage of peptides implicated in anxiety-like behavior, converg-
ing lines of evidence from rodent studies strongly implicate the
nociceptin system in regulation of anxiety states. Notably, OFQ/N
and NOP-R agonists have been shown to attenuate the expression
of anxiety-like behaviors and in a manner comparable to that of
conventional anxiolytics including diazepam (Jenck et al., 1997,
2000) and alaprozam (Jenck et al., 2000).
The attenuation of anxiety-like behaviors by OFQ/N stands in
contrast to other evidence already discussed that nociceptin pro-
motes feed-forward regulation of the HPA axis, which is often
associated with anxiety states. Moreover, stimulation of the noci-
ceptin system has also been demonstrated to enhance – rather than
attenuate – the expression of anxiety-like behavior under speciﬁc
conditions (Fernandez et al., 2004; Green et al., 2007). Therefore,
it would appear that the relationship between the emotional and
endocrine effects of nociceptin is not straightforward, nor is it
clear whether the OFQ/N system is anxiolytic or anxiogenic. In
the remainder of this section, these studies will be reviewed more
closely, and are summarized in Tables 3 and 4.
The modulatory effects of OFQ/N have been extensively stud-
ied in a variety of tests that model different aspects of anxiety
in rodents. For instance, in mice and rats central administra-
tion of OFQ/N increased the amount of time spent in the lighted
compartment of a light-dark (LD) box and enhanced open arm
exploration in the EPM test (Jenck et al., 1997; Gavioli et al., 2002;
Uchiyama et al., 2008). Likewise, systemic administration to rats
of Ro64-6198, a nonpeptide NOP-R agonist, that easily penetrates
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Table 3 | Effects of manipulation of the nociceptin system on the expression of innate (a) and learned (b) anxiety-like behavior in rodents.
Manipulation Effects of OFQ/N or analog (dose)
Behavioral test/reference Species (Route of administration) Anxiogenic behavior Non-specific behavioral responses
(a) Ethologically based tests
Light-dark (LD) box Avoidance of lighted area Locomotor activity Motor coordination
Jenck et al. (1997) Mice OFQ/N (icv) ↓ (0.3–1.0 nmole) N/A #↓ (1.0–3.0 nmole)
Fernandez et al. (2004) Rats ↑ (0.01–1.0 nmoles) Ø (0.1 nmoles) N/A
Elevated plus maze (EPM) Avoidance of open arms Locomotor activity Motor coordination
Jenck et al. (1997) Rats OFQ/N (icv) ↓ (0.03–0.3 nmole) #↓ (0.3–1.0 nmole) #↓ (1.0 nmole)
Fernandez et al. (2004) ↑ (0.01–1.0 nmole) ↓ (1.0 nmole) N/A
Gavioli et al. (2002) Mice ↓ (0.01–0.1 nmol) Ø (0.01–0.1 nmol) Ø (0.01–0.1 nmol)
Uchiyama et al. (2008) ↓ (0.1–0.32 nmol) ↓ (0.1–0.32 nmol) N/A
Jenck et al. (2000) Rats Ro64-6198 (ip) ↓ (1.0–3.2 mg/kg) Ø (1.0–3.2 mg/kg) Ø (1.0–3.2 mg/kg)
Gavioli et al. (2002) Nocistatin (icv) ↑ (0.1–3.0 pmol) Ø (0.1–3.0 pmol) Ø (0.1–3.0 pmol)
Rodi et al. (2008) Rats
CRH (1 μg/rat, icv) OFQ/N (icv) ↓ (1.8 μg/rat) N/A N/A
OFQ/N (intra BNST) ↓ (0.5 μg/rat) N/A N/A
Hole-board test Reduced exploration (head-dipping) Locomotor activity Motor coordination
Kamei et al. (2004) Mice OFQ/N (icv) ↓ (0.01 nmol) Ø (0.01 nmol) N/A
Florin et al. (1996) ↓ (0.05 nmol) N/A N/A
Novelty-induced hypophagia Hypophagia (novel environment) Hypophagia (home cage)
Goeldner et al. (2012) Mice Ro64-6198 (ip) ↓ (0.3–1.0 mg/kg) Ø (0.3–1.0 mg/kg)
Exposure to a novel environment/open ﬁeld (OF) Thigmotaxic behavior Locomotor activity Motor coordination
Green et al. (2007) Rats OFQ/N (icv) ↑ (0.01–1.0 nmoles) Ø (1.0 nmoles) N/A
OFQ/N (intra-amygdaloid) *↑ (0.1–1.0 nmoles) N/A N/A
OFQ/N (intra-BNST) *↑ (1.0 nmoles) N/A N/A
Fernandez et al. (2004) OFQ/N (icv) ↑ (0.001–1.0 nmoles) N/A N/A
Florin et al. (1996) Mice OFQ/N (icv) N/A ↑ (0.005–5.0 nmol) N/A
Jenck et al. (1997) N/A ↑ (0.1 nmole) N/A
Urocortin (0.06 nmole, icv)-induced hypolocomotion Hypolocomotion
Jenck et al. (1997) Mice OFQ/N (icv) ↓ (0.1–0.3 nmole + urocortin)
CRH-induced Hypophagia Hypophagia Hyperphagia (food-satiated or deprived rats)
Ciccocioppo et al. (2003) Rats
CRH (0.04 nmol, icv) OFQ/N (intra-BNST) ↓ (0.02–0.21 nmol) Ø (0.02–0.21 nmol)
Ciccocioppo et al. (2004) Rats
CRH (0.2 μg/rat, icv) OFQ/N (icv) ↓ (1 μg/rat) Ø (1 μg/rat)
Ro64-6198 (ip) ↓ (0.3–1.0 mg/kg) Ø (0.3–1.0 mg/kg)
(b) Models of learned anxiety or fear
Operant Conﬂict Procedure Punished responding Unpunished responding
Jenck et al. (1997) Mice OFQ/N (icv) ↑ (3 nmoles) Ø (3 nmoles)
Jenck et al. (2000) Rats Ro64-6198 (ip) ↑ (1.0 mg/kg) Ø (1.0 mg/kg)
Varty et al. (2005) ↑ (3.0–10.0 mg/kg) Ø (3.0–10.0 mg/kg)
Fear potentiated startle (FPS) Response amplitude (CS+) Response amplitude (habituation trials)
Jenck et al. (2000) Rats Ro64-6198 (ip) ↓ (3.2–10 mg/kg) Ø (3.2–10 mg/kg)
ElevatedT-maze Inhibitory avoidance behavior Locomotor activity Motor coordination
Duzzioni et al. (2011) Rats UFP-101 (icv) ↓ (1.0–10.0 nmol) *↑ or ↓ (dose dependent) N/A
Abbreviations used (those not already deﬁned inTables 1 and 2): Ro64-6198, nociceptin receptor agonist;↓ decreased expression of behavior; ↑increased expression
of behavior; Ø no effect on behavior; N/A, not applicable or effects not addressed in referenced study; # non-signiﬁcant trend toward increased or decreased expression
of behavior; *statistically signiﬁcant effect for some but not all aspects of measured behavior; CS+, presence of conditioned stimulus. Note: effects of OFQ/N or
analog on motor coordination are summarized for effective drug doses employed in other behavioral tests.
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Table 4 | Effects of targeted deletion of endogenous OFQ/N and NOP-R signaling on the expression of (a) innate and (b) learned anxiety-like or
fear-like behavior in rodents.
Effect of genetic manipulation
Behavioral test/reference Species Transgenic Model Anxiogenic behavior Non-specific behavioral responses
(a) Ethologically based tests
Light-dark (LD) box Avoidance of lit area Locomotor activity Motor coordination
Koster et al. (1999) Mice OFQ/N−/− knockout ↑ (vs OFQ/N+′ +) N/A N/A
Gavioli et al. (2007) NOP-R−/−knockout ↑ (vs NOP-R+/+) ↑ (vs NOP-R+/+) N/A
Ouagazzal et al. (2003)
Crowded housing (5/cage) ↑ (vs OFQ/N+′ +) N/A N/A
†Single-housed Ø N/A Ø
Elevated plus maze (EPM) Avoidance of open arms Locomotor activity Motor coordination
Koster et al. (1999) Mice OFQ/N−/− knockout ↑ (vs OFQ/N+′ +) Ø N/A
Gavioli et al. (2007) NOP-R−/−knockout ↑ (vs NOP-R+/+) ↑ (vs NOP-R+/+) N/A
Mamiya et al. (1998) Ø Ø Ø
Rizzi et al. (2011) Rats ↑ (vs NOP-R+/+) Ø ↑ (vs NOP-R+/+)
ElevatedT-maze Escape behavior
Gavioli et al. (2007) Mice NOP-R−/−knockout ↓ (vs NOP-R+/+)
Hole-board test Reduced exploration(head dipping) Locomotor activity Motor coordination
Gavioli et al. (2007) Mice NOP-R−/−knockout Ø N/A N/A
Marble-burying test Burying behavior
Gavioli et al. (2007) Mice NOP-R−/−knockout Ø
Novelty-induced hypophagia Hypophagia (novel environment) Hypophagia (home cage)
Gavioli et al. (2007) Mice NOP-R−/−knockout ↓ (vs NOP-R+/+) Ø
Exposure to a novel environment/open ﬁeld (OF) Thigmotaxic behavior Locomotor activity Motor coordination
Gavioli et al. (2007) Mice NOP-R−/−knockout Ø Ø N/A
Koster et al. (1999) OFQ/N−/− knockout ↑ (vs OFQ/N+′ +) ↓ (vs OFQ/N+′ +) N/A
Ouagazzal et al. (2003)
†Single-housed N/A Ø N/A
Rizzi et al. (2011) Rats NOP-R−/−knockout Ø Ø ↑ (vs NOP-R+/+)
Effect of genetic manipulation
Behavioral test/reference Species Transgenic Model Anxiogenic behavior
(b) Models of learned anxiety or fear
Acoustic startle reﬂex procedure Startle response amplitude
Ouagazzal et al. (2003)
Crowded housing (5/cage) Mice OFQ/N−/− knockout ↑ (vs OFQ/N+′ +)
†Single-housed Ø
Stress-induced analgesia (SIA) SIA
Koster et al. (1999) Mice OFQ/N−/− knockout Lack of habituation of SIA in response to repeated swim stress
NOP-R−/−, nociceptin receptor deﬁcient (knockout); NOP-R+/+, nociceptin receptor intact (wildtype); ↓ decreased expression of behavior; ↑ increased expression
of behavior; Ø, no effect on behavior; N/A, not applicable or effects not addressed in referenced study; †, single-housed mice were maintained in adjacent, transparent
cages that allowed for auditory, visual, and olfactory communication. This type of housing arrangement could have reduced the anxiogenic effects of isolation. Note:
where applicable, effects of genotype on motor coordination (↑ enhanced; ↓ impaired) are summarized for each study.
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the blood-brain barrier, attenuated open-arm avoidance in the
EPM (Jenck et al., 2000) and, in mice, increased the consumption
of a familiar and highly palatable, liquid diet in a novel envi-
ronment (Goeldner et al., 2012). These studies used ethologically
based tests, which involved measures of unconditioned responses
(e.g., approach-avoidance behavior) and are based on a rodent’s
inherent fear of unprotected, brightly lit and unfamiliar spaces.
Consequently, it is possible that OFQ/Nmay be effective in reduc-
ing anxiety-like behavior under conditions in which an anxiogenic
response is unlearned or hard-wired.
One caveat, however, is that unconditional responding is sus-
ceptible to drug effects on general activity levels (Rodgers, 1997).
Notably, the aforementioned studies used effective dose ranges
at which OFQ/N has been reported to produce either hyper- or
hypolocomotion in mice and rats (Reinscheid et al., 1995; Devine
et al., 1996; Florin et al., 1996; Rizzi et al., 2001). Moreover, at
higher doses, OFQ/N can even impair motor coordination and
balance (Jenck et al., 1997, 2000). Indeed, dose-dependent effects
of OFQ/N on locomotor activity are most apparent in the EPM.
For instance, in mice,low doses of OFQ/N (0.01 nmol, icv) atten-
uated open arm avoidance without affecting other measures of
locomotor activity (Gavioli et al., 2002), while higher doses of
OFQ/N (0.1–0.3 nmol, icv) decreased open arm avoidance and
also increased the total number of transitions between open and
closed arms (Uchiyama et al., 2008). At high doses, therefore, the
behavioral effects of OFQ/N may not be speciﬁc to the anxiolytic
properties of the neuropeptide.
Similar concerns for the behavioral effects of OFQ/N were
observed in the hole board and LD emergence tests (Florin et al.,
1996; Jenck et al., 1997; Kamei et al., 2004). In the hole board test,
OFQ/N was thought to attenuate anxiety by virtue of increas-
ing head-dipping behavior (into the holes of the apparatus),
and this occurred without changing general activity level (Kamei
et al., 2004). Moreover, this occurred at the lowest dose tested
(0.01 nmol, icv; Kamei et al., 2004). However, in other stud-
ies the increased exploration (i.e., head dipping) in the hole
board test, as well as emergence into light in the LD box test,
could not be differentiated from the locomotor-stimulating prop-
erties of the OFQ/N dose range tested (0.05–1.0 nmol, icv;
Florin et al., 1996).
One further consideration is that the speciﬁc parameters of
locomotion may inform interpretation of the locomotor effects of
a given treatment. For instance, although OFQ/N (0.05–0.5 nmol,
icv) produced a general hyperlocomotion in mice subjected to an
unfamiliar or novel environment (Florin et al., 1996; Jenck et al.,
1997), this was parsed into increased horizontal movement and
increased vertical movement (e.g., rearings). Such a combination
of movements might be considered an index of increased explo-
ration and possibly reduced anxiety in animals. Indeed, when
hypolocomotion was induced by the CRH receptor II agonist uro-
cortin (a purported anxiogenic effect), OFQ/N (0.1–0.3 nmol,
icv) reversed this effect, and in a manner comparable to that
of diazepam (Jenck et al., 1997). This may support the concept
introduced above with regard to ethological tests: that OFQ/N
is anxiolytic during states of heighted anxiety, serving to inter-
fere with other neurochemical systems that initially trigger the
anxiety-like behavior.
The anxiolytic properties of OFQ/N signaling have also been
demonstrated in models of learned anxiety and/or fear (Jenck
et al., 1997, 2000; Varty et al., 2005). In one study, OFQ/N atten-
uated response inhibition in a modiﬁed Geller-Seifter conﬂict
test (Jenck et al., 1997). In this test, food-deprived mice are ﬁrst
trained to lever-press for food reinforcement. After training, mice
are subjected to alternating non-conﬂict and conﬂict sessions, in
which bar presses are either reinforced with food (non-conﬂict)
or result in food delivery and simultaneous foot-shock (conﬂict).
In vehicle-treated mice, foot-shock resulted in a selective inhibi-
tion of lever-press behavior. Conversely,OFQ/N increased operant
responding during conﬂict sessions (Jenck et al., 1997), as did
Ro64-6198 in rats (Jenck et al., 2000; Varty et al., 2005). This sug-
gests that OFQ/N may reduce the degree of task-speciﬁc anxiety
associated with punished responding.
It should be noted that OFQ/N is a potent orexigenic agent
(Pomonis et al., 1996; Stratford et al., 1997; Polidori et al., 2000).
In fact, administration of OFQ/N into the lateral or third ventri-
cles stimulates feeding in non-food deprived rats (Pomonis et al.,
1996; Polidori et al., 2000). Moreover, site-speciﬁc microinjec-
tion of OFQ/N into brain regions implicated in the regulation
of food intake (Stratford et al., 1997; Polidori et al., 2000) induces
hyperphagia in free-feeding rats. Therefore, in tasks that involve
appetitive behavior, it is possible that the hyperphagic effects of
nociceptin contribute to changes in behavioral responses observed
in food-deprived animals, such as those trained in the Geller-
Seifter conﬂict test. However, since neither OFQ/N nor Ro64-6198
affected lever press behavior during non-conﬂict sessions (i.e.,
unpunished responding), it is likely that the OFQ/N-induced
increase in punished responding is speciﬁc to the anxiolytic
properties of OFQ/N (Jenck et al., 1997, 2000; Varty et al., 2005).
Finally, OFQ/N signaling attenuates anxiogenic behavior in
other models of conditioned or learned emotional responses, such
as the fear-potentiated startle procedure (Jenck et al., 2000). In
this paradigm a previously neutral, conditional stimulus (CS; e.g.,
a light) is explicitly paired with the presentation of an aversive,
unconditional stimulus (US; e.g., foot-shock). Following repeated
CS-US presentations, an association between the two stimuli is
formed such that the light comes to predict the occurrence of
foot-shock. After conditioning, the startle response to an acoustic
stimulus (e.g., a short burst of white noise) is measured in the
absence (CS−) and presence (CS+) of the CS on alternating tri-
als. The magnitude of startle potentiation, or increase in response
amplitude on trials in which the CS is present (CS+ trials), rela-
tive to trials in which the CS is absent (CS−), is then taken as an
index of learned fear. Thus, animals should exhibit a greater startle
response on trials in which the CS is presented in conjunctionwith
the acoustic stimulus. Consistent with the anxiolytic-like effects
of OFQ/N and Ro64-6198 in the Geller-Seifter conﬂict test (Jenck
et al., 1997, 2000; Varty et al., 2005), systemic administration of
Ro64-6198 attenuated the magnitude of startle potentiation in
rats (Jenck et al., 2000). This reinforced the notion that fear and/or
anxiety can be reduced after stimulation of the OFQ/N receptor
NOP.
The use of transgenic mice deﬁcient in various components of
the OFQ/N system have also suggested that OFQ/N is involved
in emotion regulation. For example, mutant mice lacking the
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OFQ/N gene (OFQ/N−/−) exhibited increased avoidance behav-
ior in the EPM (Koster et al., 1999). More speciﬁcally, OFQ/N−/−
mice made fewer entries into and spent less time in the open
arms of the EPM. Similarly, in the LD emergence test, OFQ/N−/−
mice, when compared to wildtype mice, spent less time exploring,
and showed a higher latency to ﬁrst enter, the lighted compart-
ment. Mutant mice also showed a reduction in free exploration in
the OF test, as evidenced by increased thigmotaxic behavior and
hypolocomotion (Koster et al., 1999). Collectively, these ﬁndings
provided converging evidence that endogenous OFQ/N signaling
mediates behavioral responding in models of innate anxiety.
Interestingly, there is evidence that the behavioral phenotype
of OFQ/N−/− mice is inﬂuenced by social housing conditions
(Koster et al., 1999; Ouagazzal et al., 2003). When maintained
under crowded housing conditions (5 mice/cage), OFQ/Nmutant
mice displayed greater home-cage aggression andheightened emo-
tional reactivity in unconditioned (LD box) and conditioned
(acoustic startle) response tests. Interestingly, when mice were
housed individually no behavioral differences were observed
between the genotypes (Ouagazzal et al., 2003). Although isolation
is also considered to be stressful the authors noted that single-
housed mice were maintained in adjacent, transparent cages that
allowed for auditory, visual, and olfactory communication. By
providing some degree of interaction this type of housing arrange-
ment could have reduced the anxiogenic effects of isolation.
Nonetheless, these ﬁndings suggest that deﬁcientOFQ/N signaling
may confer a vulnerability to stress, and in this case, to the chronic
stress produced by crowded housing conditions (Ouagazzal et al.,
2003). More broadly, these data implicate endogenous OFQ/N in
stressor-induced behavioral adaptation (Ouagazzal et al., 2003).
In good agreement with this idea, Koster et al. (1999) disrupted
the ppOFQ/N gene, and reported that group-housed OFQ/N−/−
mice failed to adapt to repeated stressor exposure. Speciﬁcally,
mice were subjected to a forced swim stressor, and adaptation to
repeated swim was assessed by habituation of stress-induced anal-
gesia (SIA). In contrast towildtypemice,OFQ/N−/− mice failed to
adapt to repeated forced swim exposure and continued to exhibit
SIA after each trial (Koster et al., 1999). These ﬁndings suggest
that OFQ/N may be needed to promote behavioral resilience and
maintenance of normal physiological functions during periods of
repeated or chronic stress.
Though evidence from knockout studies corroborates the idea
that OFQ/N likely serves to dampen the expression of anxiogenic-
like behavior, it should be noted that the aforementioned use of
OFQ/N−/− mice involved a disruption in the ppOFQ/N gene.
As noted earlier, this precursor peptide is cleaved to form other
biologically active peptides (Meunier et al., 1995; Okuda-Ashitaka
et al., 1998; Reinscheid et al., 2000; Mogil and Pasternak, 2001),
such as nocistatin, which can have opposite biological effects to
that of OFQ/N (Okuda-Ashitaka et al., 1998; Gavioli et al., 2002).
For example, central administration of nocistatin alone increased
anxiogenic behavior in rats tested in the EPM, and furthermore,
abrogated the anxiolytic-like effects of OFQ/N in this same test
(Gavioli et al., 2002). Therefore, behavioral data from mice with
disruptions to ppOFQ/N must be carefully interpreted.
Nonetheless, it is encouraging that targeted deletions of NOP-
R can produce a similar anxiogenic proﬁle in both mice (Gavioli
et al., 2007) and rats (Rizzi et al., 2011). For instance, NOP-R
knockout animals (NOP-R−/−) spend less time in the osten-
sibly anxiety-provoking open areas of the EPM (Gavioli et al.,
2007; Rizzi et al., 2011) and the illuminated region of the LD box
(Gavioli et al., 2007). However, this not a consistent observation
(Mamiya et al., 1998; Gavioli et al., 2007). Whereas Gavioli et al.
(2007) describe an anxiogenic-like proﬁle for NOP-R−/− mice
in the EPM, Mamiya et al. (1998) observed no behavioral differ-
ences between the wildtype and mutant genotypes also tested in
the EPM. While not easily explained, it should be noted, that the
genetic background on which the NOP-R mutation was gener-
ated varied between the two studies. As this is a critical factor in
behavioral phenotypes of genetically modiﬁed mice, particularly
with respect to anxiogenic behavior (Anisman et al., 2008), differ-
ences in background strain could have accounted for the disparate
ﬁndings. For example, attending only to the data from wildtype
mice, baseline levels of anxiety differed signiﬁcantly between the
studies (Mamiya et al., 1998; Gavioli et al., 2007), attesting to the
importance of background genetics modifying the expression of
gene deletions (Anisman et al., 2008).
Leaving aside the issue of background genetics in the inter-
pretation of speciﬁc gene deletions, it should be emphasized that
variations in the type of behavioral test can also reveal different
results. For instance, Gavioli et al. (2007) report no behavioral dif-
ferences betweenNOP-R+/+ andNOP-R−/− mice in theOF, hole
board andmarble burying tests. These ﬁndings stand in contrast to
other evidence that pharmacological stimulation of NOP-R atten-
uates anxiogenic-related behaviors in the OF and hole board tests
(Florin et al., 1996; Jenck et al., 1997, 2000; Kamei et al., 2004).
However, a variety of factors could have accounted for the dis-
crepant ﬁndings. As noted by Gavioli et al. (2007), differences
in the experimental conditions between their study and others
(Florin et al., 1996; Jenck et al., 1997, 2000; Kamei et al., 2004)
could have limited their ability to detect differences in anxiogenic-
like behavior between the genotypes. It is also possible that other
biological mechanisms compensated for the loss of NOP-R signal-
ing throughout development and that these compensatory systems
were sufﬁcient to support normal, behavioral responding under
certain experimental conditions.
Adding to the confusion emerging from transgenicmouse stud-
ies, NOP-R−/− mice exhibited an anxiolytic-like proﬁle when
tested in the novelty-induced suppressed feeding behavior test
(Gavioli et al., 2007). Brieﬂy, in this test food-deprived mice are
placed into the corner of an OF that, prior to testing, was baited
with food pellets located in the centermost region of the OF. Dur-
ing testing, the latency to venture out and eat, and the amount
consumed (over a 5 min period), was then scored for each animal.
Immediately thereafter, mice were returned to their home cages
where they were scored using the same behavioral parameters.
Anxiety generated by the novel and ostensibly aversive environ-
ment (the OF) suppressed the motivation to seek and consume
food, resulting in an increased latency to ﬁrst eat, as well as a
reduced food intake. However, upon returning to their home cages,
animals quickly approached and consumed a greater amount of
food than in the novel environment. Unexpectedly, NOP-R−/−
mice exhibited a reduced latency to eat and consumed a greater
amount of food than wildtype controls in the OF (Gavioli et al.,
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2007). This apparent anxiolytic phenotype of NOP-R−/− mice
could not be accounted for by differences in appetite, as the body
mass lost during deprivation was equivalent between the geno-
types. Moreover, NOP-R−/− and NOP-R+/+ mice consumed the
same amount of food when returned to their home cages (Gavioli
et al., 2007).
A different study byMallimo et al. (2010) usedORL-1−/− mice
(i.e.,NOP-Rdeﬁcient) that received saline and immunologic treat-
ment, and were tested within hours of treatment or several days
later. Testing of mice included gustatory neophobia, OF behavior
and exposure to a large and unfamiliar, novel object (to test for
object neophobia). Of relevance to the current discussion is the
behavior of the saline injected (ip) mice. In these mice, it was
observed that relative to saline-injected ORL-1+/+ mice, gusta-
tory neophobia was attenuated in ORL-1−/− mice, which is in
keeping with the observations of Gavioli et al. (2007) discussed
above. Furthermore, and again similar to Gavioli et al. (2007), OF
behavior tested several days later was not different between the
ORL-1−/− and ORL-1+/+ mice. However, in ORL-1−/− mice,
approach and contact with a novel object placed into the OF, was
signiﬁcantly reduced, and time spent away from the object was
signiﬁcantly increased (Mallimo et al., 2010).
These observations suggest that the impact of OFQ/N recep-
tor deletion produces a complicated phenotype that appears to
depend on the type of testing conducted on the animals. In par-
ticular, the use of an appetitive paradigm, such as those described
above, does not unmask an anxiety-like pattern of behavior in
mice rendered NOP-R deﬁcient. Furthermore, there are alterna-
tive interpretations of the data that could be posited. For instance,
a shorter latency to enter the centermost region of an OF to con-
sume food, may reﬂect impulsive behavior. In line with this idea,
UFP-101, a NOP-R antagonist, reduced the latency to ﬁrst exit
the closed arm of an elevated T-maze (ETM) and enter into an
open, unprotected arm (Duzzioni et al., 2011). Although a reduced
latency could be considered an index of a diminished anxiety-like
behavior, it could also be argued that rats with shorter exit latencies
are more impulsive than animals demonstrating an appropriate,
inhibitory avoidance response. Although speculative, this hypoth-
esis could account for some of the inconsistencies observed in
the behavioral phenotype of NOP-R−/− mice. At the very least,
it is apparent that endogenous NOP-R differentially modulates
anxiogenic-like behavior across different tests of anxiety, even
when the behavioral methods employed intend to model the same
aspects of anxiety (e.g., innate anxiety).
CONCLUDING POINTS
In general, most of the behavioral evidence suggests that under
conditions of stress, exposure to novel contexts, and learned anx-
iety and/or fear responses, OFQ/N is recruited to modulate the
intensity or severity of behavioral change. Conceptually, it is
tempting to think that OFQ/N serves as an attenuating inﬂuence
on anxiety, although additional research is required to conﬁrm
this hypothesis, since not all of the data gathered to date ﬁt neatly
into this interpretation (Fernandez et al., 2004; Green et al., 2007).
Still, it should be noted that the anxiogenic and anorectic effects of
CRH are inhibited byOFQ/N (Ciccocioppo et al., 2003, 2004; Rodi
et al., 2008), which reinforces the notion that OFQ/N functions
as an opposing inﬂuence on neurochemical systems activated by
stress. However, the precise effects of such opposition needs to be
clariﬁed. Interestingly, a recent study found that individuals who
suffer from PTSD, and carry a single-nucleotide polymorphism
for the human opioid receptor-like 1 gene (Oprl1), showed greater
functional connectivity between the amygdala and the insula dur-
ing exposure to fearful faces (Andero et al., 2013). Although not
a therapeutic study, this study does provide the opportunity to
determine whether PTSD symptoms might be better managed by
administering OFQ/N receptor agonists. However, further work
is going to be needed, since in the same report, ORL-1 receptor
stimulation in mice prevented the consolidation of fear mem-
ory after an aversive event (ibid). How to implement treatments
like this therapeutically without affecting other memory processes
necessary for optimal cognitive functioning will require further
analysis.
OFQ/N AND INFLAMMATION
It is well established that immune factors – primarily cytokines –
can impact neurobiological functions under normal and clinical
conditions (Dantzer et al., 2008). Cytokines are immune-derived
intercellular messengers that are involved in systemic inﬂamma-
tion, and their identiﬁcation in damaged brain tissue has focused
attention on neuroinﬂammatory mechanisms of brain dysfunc-
tion, as well as their possible contributions to brain plasticity and
repair. Brain cytokines originate from glial cells, such as astro-
cytes, oligodendrocytes, and in particular, microglia (Ransohoff
and Perry, 2009; Graeber et al., 2011). The regulation of cytokine
synthesis and release is carefully orchestrated, since changes in the
magnitude and duration of cytokine levels may modify a range of
cognitive and emotional functions, including those aligned with
classical indices of depressive symptomatology. Indeed, studies
of immune challenge (eg., using endotoxin or lipopolysaccha-
ride, LPS), have shown a tripartite of proinﬂammatory cytokines
- interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-alpha
(TNFα) – to be the most signiﬁcant and potent inﬂuences on a
variety of neural, endocrine and behavioral measures (Dantzer
et al., 2008). However, it is now evident that these and other
cytokines are part of the brain’s neurochemical milieu operating
independently of immune challenge, and which can be elicited
by neurotransmitter and neuropeptide systems activated by psy-
chogenic stressors (Albrecht et al., 2010; Spulber and Schultzberg,
2010; Perez Nievas et al., 2011; Stipursky et al., 2011;Wager-Smith
and Markou, 2011; Barnum et al., 2012; Santello et al., 2012).
An exciting development over the past decade is that OFQ/N
is involved in regulation of neuroinﬂammatory and immuno-
logical processes. Orphanin FQ/nociceptin and its receptor are
expressed in various peripheral tissues (Lachowicz et al., 1995;
Mollereau et al., 1996) including immune cells and lymphoid
organs (Wang et al., 1994), and similar to endogenous opioids,
the OFQ/N system plays a role in immunomodulation (Halford
et al., 1995; Kawashima et al., 2002; Kato et al., 2005; Rossi-George
et al., 2005; Goldfarb et al., 2006; Miller and Fulford, 2007; Finley
et al., 2008; Leggett et al., 2009b). Stimulation of NOP-R enhances
or suppresses expression of proinﬂammatory cytokines (Buzas
et al., 2002; Kawashima et al., 2002; Fu et al., 2006) or chemokines
(Finley et al., 2008), stimulates chemotaxis (Serhan et al., 2001;
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Trombella et al., 2005), and modulates activation of the HPA axis
in response to inﬂammatory stimuli (Leggett et al., 2009b;Mallimo
et al., 2010). In general, the hypothesized role of the nociceptin
system is believed to be anti-inﬂammatory, a function that may
be exerted through regulation of cytokine expression. Figure 3
provides a schematic illustration of the major ﬁndings discussed
below, regarding the immunomodulatory role of OFQ/N in the
periphery and CNS.
In the immune system, Miller and Fulford (2007) determined
that OFQ/N secretion from lymphocytes and splenocytes (in
vitro) is increased following exposure to various inﬂammatory
mediators such as T (Concanavalin A; Con A) and B cell (LPS)
mitogens, the proinﬂammatory cytokines IL-1β and TNFα, and
synthetic glucocorticoids. Moreover, OFQ/N suppressed produc-
tion of IL-2 from cultured splenocytes and signiﬁcantly attenuated
splenocyte proliferation in response to Con A stimulation, an
effect that was inhibited by ORL-1 receptor antagonists (Miller
and Fulford, 2007). There is also evidence to suggest that OFQ/N
may have immunomodulatory properties in vivo. For instance,
ORL-1−/−receptor deﬁcientmice (ORL-1−/−) exhibited an exag-
gerated splenic IL-2 response 4 h after systemic challenge with the
bacterial T lymphocyte“superantigen,” staphylococcal enterotoxin
A (SEA; Mallimo et al., 2010). This ﬁnding is in good agreement
with that of Miller and Fulford (2007) and the idea that signal-
ing through the OFQ/N receptor limits the production of IL-2
following T cell activation.
On the other hand, intraperitoneal injection (ip) of OFQ/N to
C57BL/6mice, prior to challenge with SEA, produced an enhance-
ment of splenic TNFα and IFNγ mRNA expression and increased
plasma levels of TNFα (Goldfarb et al., 2006). Conversely, in the
same study, ppOFQ/N−/− mice challenged with SEA showed
diminished mRNA for TNFα and IFNγ (ibid). The stimulatory
FIGURE 3 | Major, immunomodulatory effects of OFQ/N in the periphery
(A), feed-forward effects of OFQ/N on the hypothalamic-pituitary-
adrenal (HPA) axis response to systemic immune stress (B) and
immunomodulatory effects of OFQ/N in the central nervous system
(CNS; C). In general, the hypothesized role of the nociceptin system is
believed to be anti-inﬂammatory, a function that may be exerted through
regulation of cytokine expression. In response to a wide variety of
immunologic stimuli (Con A, concanavalin A; LPS, lipopolysaccharide; IL-1β,
Interleukin-1 beta; TNFα, tumor necrosis factor alpha; SEA, staphylococcal
enterotoxin A) OFQ/N inhibits (red box with minus) or enhances (green box
with plus) the release of inﬂammatory cytokines (TNFα, interleukin-2; IL-2 and
interferon gamma; IFNγ) from splenocytes and lymphocytes and enhances
SEA-induced elevations in circulating TNFα. Nociceptin also modulates
T-lymphocyte proliferation and activation following superantigenic challenge
with staphylococcal enterotoxin B (SEB;A). In line with its feed-forward
effects on the HPA axis response to psychogenic stress, OFQ/N exerts
stimulatory effects on the HPA axis response to systemic immune stress.
Speciﬁcally, nociceptin signaling prolongs elevations in circulating CORT
induced by systemic administration of SEA or LPS (B). In the central nervous
system (CNS), OFQ/N modulates the release inﬂammatory cytokines.
Notably, nociceptin signaling appears to regulate, in a cell-speciﬁc manner,
the expression of IL-1β. In response to traumatic injury or LPS, OFQ/N
attenuates the release of IL-1β from microglial cells and astrocytes.
Conversely, nociceptin signaling enhances the release of IL-1β from neurons
(C). Abbreviations used: corticotropin releasing hormone; CRH,
adrenocorticotropin hormone; ACTH, paraventricular nucleus; PVN, bed
nucleus of stria terminalis; BNST, central amygdala; CeA, medial amygdala;
MeA, basolateral amygdala; BLA, basolateral amygdala.
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effect of OFQ/N on TNFα and IFNγ may be necessary to ensure
optimal levels of cytokine production at later time points follow-
ing T cell stimulation. In line with this idea, ORL-1−/− mice
exhibited an attenuated splenic, TNFα response 4 h after systemic
challenge with SEA (Mallimo et al., 2010). Collectively, these ﬁnd-
ings suggest that activation of the nociceptin system may play
an important role in the balance of pro- and anti-inﬂammatory
cytokine production. These effects of SEA may involve interac-
tions at the level of T lymphocytes. That is, SEA is selective for
T cells (Goldfarb et al., 2006), and T cells are known to express
NOP-R, the receptor for OFQ/N (Peluso et al., 1998). Indeed,
addition of OFQ/N to human T cell cultures stimulated with
another superantigen, staphylococcal enterotoxin B (SEB), result
in enhanced proliferation, but reduced TNFα production (Waits
et al., 2004). Interestingly, restimulationof the sameTcells resulted
in OFQ/N causing a reduction in proliferative responding (ibid).
A later study showed that cultured puriﬁed CD4+ T cells from
human peripheral blood had attenuated proliferative responding
to primary SEB exposure when OFQ/N was introduced into cell
culture (Fiset et al., 2003; Easten et al., 2009). From these stud-
ies it is evident that OFQ/N has immunomodulatory properties
that can target T cell function, although the direction of its effects
on cytokine production and T cell proliferation require further
characterization.
In keeping with in vivo studies that provided good evidence for
OFQ/N-dependent immunomodulation (Goldfarb et al., 2006),
additional studies are available to show the clinical applicabil-
ity of these effects. In a rat study of experimental colitis, it was
demonstrated that pathology and inﬂammatory cytokine pro-
duction (eg., IL-1β) were diminished after two daily injections
of low dose (0.02 and 0.2 nmol/Kg) OFQ/N, but were exacer-
bated when the dose was substantially increased (20 nmol/Kg;
Petrella et al., 2013). The implications of this ﬁnding are con-
sistent with an earlier observation that OFQ/N elevations may
negatively impact survival during infection. That is, subsequent
to the induction of sepsis by cecal ligation and puncture, OFQ/N
administration to rats increased mortality, while NOP-R antago-
nist treatment attenuated various cellular and cytokine parameters
of inﬂammation, and reduced mortality (Carvalho et al., 2008).
Corresponding data in human clinical situations has been noted,
with higher correlations of plasma OFQ/N in non-surviving sep-
tic patients suggesting that antagonism of OFQ/N may be a
potential immunotherapeutic manipulation that may aid recov-
ery (Serrano-Gomez et al., 2011). Overall, while little is known
about the precise interactions between OFQ/N and the immune
system, there is compelling evidence to explore this relationship
further and elucidate the relevance of this to immunopathological
and inﬂammatory disorders.
It is well established that systemic immune responses can pro-
duce changes in various neurobiological outcomes. In keeping
with various CNS changes in neuropeptides and monamine neu-
rotransmitters after immune challenge (Anisman et al., 2008),
mice challenged with the bacterial T cell superantigen, SEA,
showed increased ppOFQ/N mRNA in the hypothalamus and
amygdala (Kawashima et al., 2002). In addition, SEA challenge
activates the HPA axis and neuronal induction of the immedi-
ate early gene c-fos in various limbic brain regions, including the
amygdala and hypothalamus (Rossi-George et al., 2005). Since
these effects are known to depend on TNF (Rossi-George et al.,
2005), it is possible that SEA-induced ppOFQ/N mRNA changes
in thebrain, are similarly dependent on thepresenceof TNF.More-
over, in the absence of ORL-1 signaling, the duration of the plasma
CORT response to SEA (Mallimo et al., 2010) and to LPS (Leggett
et al., 2009a) is reduced, suggesting that mobilization of central
OFQ/N may promote a prolongation of the HPA axis response to
systemic immune stress.
In addition toT cell antigens, strongproinﬂammatory inducers,
such as LPS,which targetsmonocytes andmacrophages, have been
shown to induce OFQ/N production by cultured sensory neurons
obtained from the dorsal root ganglion, an effect that appears to be
dependent on the Toll-like receptor 4 (TLR4; Acosta and Davies,
2008). This may be relevant to nociception, as inﬂammation-
related pain may be due to regulation of the hypoalgesic effects
of OFQ/N, suggesting that NOP-R and OFQ/N are recruited by
inﬂammatory stimuli to coordinate and control levels of pain per-
ception (Depner et al., 2003; Chen and Sommer, 2007; Fu et al.,
2007a). For instance, formalin and zymosan induce inﬂammation
and induction of pain, although lower thresholds of pain sensi-
tivity were evident in mice that lacked either ppOFQ/N and/or
NOP-R (Depner et al., 2003). Furthermore, areas of inﬂammation
in peripheral, as well as central, nervous tissue most likely attract
inﬁltration of leukocytes (Prendergast and Anderton, 2009). Such
cellular inﬁltrates may further contribute to the concentration
of local neuron-derived OFQ/N, since neutrophils are known to
produce OFQ/N (Fiset et al., 2003). Finally, as detailed below,
astrocytes express NOP-R and cytokine production by astrocytes
can be inhibited by OFQ/N, an effect which represents one mech-
anism by which OFQ/N may reduce pain sensitivity (Fu et al.,
2007b).
In recent years there has been a resurgence of interest in glial
cell function in the CNS, and in particular, how this contributes
to and/or regulates neuroinﬂammatory processes in neurodegen-
erative conditions. The inﬂuence of OFQ/N on glial function has
been suggested through a variety of different in vitro and in vivo
studies. For example, NOP-R engagement may inﬂuence oligo-
dendrocyte development, since the modulation of myelin basic
protein concentrations subsequent to prenatal treatment with the
opioid agonist, buprenorphine, were shown to be dependent on
NOP-R expression (Eschenroeder et al., 2012). Similarly, with
regard to astrocyte function, NOP-R knockout mice treated with
methamphetamine have augmented GFAP expression in the stria-
tum (Sakoori and Murphy, 2010), which is in keeping with other
evidence that spinal cord astrocyte activation and in vitro cytokine
production by astrocytes is attenuated by OFQ/N via ORL-1,
which is expressed on astrocytes (Fu et al., 2007b). Interestingly,
ppOFQ/NmRNA is increased in astrocytes treated withmorphine
(Takayama and Ueda, 2005), while LPS, and various proinﬂam-
matory cytokines (eg., tumor necrosis factor and interleukin-1)
can increase astrocyte concentrations of immunoreactive OFQ/N
and ppOFQ/N mRNA (Buzas et al., 2002). Finally, following
neural trauma in rats, LPS treatment increased OFQ/N co-
localizedwithbrain astrocytes (Zhao et al., 2002). This observation
was made in the context of a corresponding investigation of
microglial cells, and is perhaps the only major instance where
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OFQ/N was linked to this intensively studied category of glial
cells.
Microglia essentially are the tissue macrophages of the brain
and spinal cord, and as such, likely exert an “immune-like”
inﬂuence through phagocytosis and production of proinﬂamma-
tory cytokines like TNFα and IL-1β. In the study by Zhao et al.
(2002), rats given icv infusion of OFQ/N showed a signiﬁcantly
reduced number of activated microglia following neural trauma.
In addition, LPS induced upregulation of IL-1βmRNA in cultured
microglial cells, and this was inhibited by application of OFQ/N
(Fu et al., 2006). This effectwas blocked by co-administration of an
ORL-1 receptor antagonist, conﬁrming that downregulation of Il-
1βmRNA transcripts inmicroglia of theCNS isORL-1 dependent.
However, when applied to cultured neurons, OFQ/N signiﬁcantly
increased LPS-induced upregulation of IL-1β mRNA (Fu et al.,
2006). The differential effect of OFQ/N on IL-1β gene expression
on microglial and neuronal preparations was suggested to reﬂect
a disturbance in the endogenous synaptic structural arrangement
between these cell types. Thus, microglia in vivo may exert a direct
inhibitory action on neurons and when this connection is dis-
turbed, neurons may upregulate IL-1β mRNA instead (Fu et al.,
2006). This is a compelling hypothesis, that is hampered by a rel-
ative paucity of additional studies to corroborate and expand on
the effects of OFQ/N on microglial cells.
In conclusion, although relatively small, there is a potentially
signiﬁcant literature relating OFQ/N to glial cell function. A com-
pelling view that might be elaborated and pursued is that of
OFQ/N mediated reduction of proinﬂammatory cytokine pro-
duction during various conditions of trauma, degeneration and
systemic inﬂammation due to infection and other immunolog-
ically relevant conditions (eg., autoimmune disease). It seems
plausible, for example, that OFQ/N may also serve to modify the
various sickness behaviors – cognitive, motoric and emotional –
that arise from exposure to immunological stimuli. This would ﬁt
the overall – but not overwhelming – view that OFQ/N serves to
attenuate stress-related behavioral reactions, as reviewed earlier.
Extending this idea further, it has been demonstrated that stress
can activatemicroglial cells in the brain (Sugama et al., 2007, 2009;
Hinwood et al., 2012), and furthermore, stress can also increase
the number of astrocytes that express IL-1β (Sugama et al., 2011).
Given that psychogenic and immunologic stressors can increase
OFQ/N expression in the brain (Kawashima et al., 2002; Nativio
et al., 2012), it could be hypothesized that an increase in OFQ/N
may serve to regulate glial cell activation and the production of
cytokines, like IL-1β (Zhao et al., 2002).Whether such interactions
exist between central OFQ/N changes and neuroinﬂammatory
events remains to be determined.
SUMMARY AND FUTURE DIRECTIONS
The current review has focused on bringing together three ele-
ments of OFQ/N biology that are potentially linked, and may
hold promise for future studies on brain health and neuroplastic-
ity. Given that many of the studies addressing the role of OFQ/N
on the HPA axis and anxiety-related behavior have focused on
acute stressor exposure, greater attention is needed to address the
relationship of OFQ/N to neuroplasticity during conditions of
chronic stress. Chronic stress has long been associated as a con-
tributor and/or trigger for anxiety and mood disorders(Charney,
2003; Feder et al., 2009), and the pursuit of the molecular and cel-
lular targets of stress-activated neurotransmitter systems (eg., the
monoamines) has shifted to the importance of neuroinﬂamma-
tory cytokines and glial cells, which express receptors for multiple
neurotransmitters (Kettenmann et al., 2011). Indeed, as stated
above, microglial cells, are activated under a range of condi-
tions, including strokes, physical trauma, demyelination, and
neurodegeneration or neuronal cell death (Ransohoff and Perry,
2009). Of particular interest is that the activated phenotype of
a microglial cell can be produced by in vitro exposure to neuro-
transmitters (eg., norepinephrine; Heneka et al., 2010), as well as
psychogenic stressors, which increase neurotransmitter synthesis
and release(Anisman et al., 2005). Indeed, psychogenic stressors
alone, in the absence of immune activation in the periphery, can
activate brain microglial cells and modify cytokine levels in the
brain (Frank et al., 2007;Wohleb et al., 2011; Hinwood et al., 2012;
Gibb et al., 2008, 2011).What is relevant and novel to this scenario
is the knowledge that OFQ/N plays an immunomodulatory role
that can modify a number of proinﬂammatory cytokines, includ-
ing IL-1β, TNF-α and IL-2. This serves to move the relationship
of OFQ/N to stress and behavior, into a scheme that also incorpo-
rates the contribution of neuroinﬂammatory functions that might
be regulated or modiﬁed by OFQ/N. This new direction may
yield clues for the treatment of neuropsychiatric clinical condi-
tions, in which neuroinﬂammation is suspected of contributing to
depression, cognitive decline and neurodegeneration.
REFERENCES
Acosta, C., and Davies, A. (2008).
Bacterial lipopolysaccharide regu-
lates nociceptin expression in sen-
sory neurons. J. Neurosci. Res. 86,
1077–1086. doi: 10.1002/jnr.21565
Albrecht, J., Sidoryk-Wegrzynowicz,
M., Zielinska, M., and Aschner,
M. (2010). Roles of glutamine
in neurotransmission. Neu-
ron Glia Biol. 6, 263–276. doi:
10.1017/S1740925X11000093
Altier, C., and Zamponi, G. W.
(2008). Signaling complexes of
voltage-gated calcium channels and
G protein-coupled receptors. J.
Recept. Signal Transduct. Res. 28, 71–
81. doi: 10.1080/10799890801941947
Andero, R., Brothers, S. P., Jovanovic,
T., Chen, Y. T., Salah-Uddin,
H., Cameron, M., et al. (2013).
Amygdala-dependent fear is regu-
lated by Oprl1 in mice and humans
with PTSD. Sci. Transl. Med. 5,
188ra173.
Anisman, H., Merali, Z., and Hay-
ley, S. (2008). Neurotransmitter,
peptide and cytokine processes
in relation to depressive disorder:
comorbidity between depression
and neurodegenerative disor-
ders. Prog. Neurobiol. 85, 1–74.
doi: 10.1016/j.pneurobio.2008.01.
004
Anisman, H., Merali, Z., Poulter, M.
O., and Hayley, S. (2005). Cytokines
as a precipitant of depressive ill-
ness: animal and human studies.
Curr. Pharm. Des. 11, 963–972. doi:
10.2174/1381612053381701
Barnum, C. J., Pace, T.W., Hu, F., Neigh,
G. N., and Tansey, M. G. (2012). Psy-
chological stress in adolescent and
adult mice increases neuroinﬂam-
mation and attenuates the response
to LPS challenge. J. Neuroinﬂamma-
tion 9, 9. doi: 10.1186/1742-2094-
9-9
Bianchi, C., Marani, L., Barbi-
eri, M., Marino, S., Beani, L.,
and Siniscalchi, A. (2004). Effects
of nociceptin/orphanin FQ and
endomorphin-1 on glutamate and
GABA release, intracellular [Ca2+]
and cell excitability in primary cul-
tures of rat cortical neurons. Neu-
ropharmacology 47, 873–883. doi:
10.1016/j.neuropharm.2004.06.017
Bunzow, J. R., Saez, C., Mortrud,
M., Bouvier, C., Williams, J. T.,
Low, M., et al. (1994). Molecular
cloning and tissue distribution of a
putative member of the rat opioid
receptor gene family that is not a
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 173 | 14
“fncel-07-00173” — 2013/10/4 — 21:26 — page 15 — #15
Mallimo and Kusnecov Orphanin FQ/nociceptin, stress, neuroinﬂammation
mu, delta or kappa opioid receptor
type. FEBS Lett. 347, 284–288. doi:
10.1016/0014-5793(94)00561-3
Buzas, B., Rosenberger, J., Kim, K. W.,
and Cox, B. M. (2002). Inﬂammatory
mediators increase the expression of
nociceptin/orphanin FQ in rat astro-
cytes in culture. Glia 39, 237–246.
doi: 10.1002/glia.10106
Carvalho, D., Petronilho, F., Vuolo,
F., Machado, R. A., Constantino,
L., Guerrini, R., et al. (2008). The
nociceptin/orphaninFQ-NOPrecep-
tor antagonist effects on an animal
model of sepsis. Intensive Care Med.
34, 2284–2290. doi: 10.1007/s00134-
008-1313-3
Cavallini, S., Marino, S., Beani,
L., Bianchi, C., and Siniscalchi,
A. (2003). Nociceptin inhibition
of acetylcholine efﬂux from differ-
ent brain areas. Neuroreport 14,
2167–2170. doi: 10.1097/00001756-
200312020-00007
Charney,D. S. (2003). Neuroanatomical
circuits modulating fear and anxi-
ety behaviors. Acta Psychiatr. Scand.
Suppl. 38–50. doi: 10.1034/j.1600-
0447.108.s417.3.x
Chen, Y., and Sommer, C. (2007). Acti-
vation of the nociceptin opioid sys-
tem in rat sensory neurons produces
antinociceptive effects in inﬂamma-
tory pain: involvement of inﬂamma-
tory mediators. J. Neurosci. Res. 85,
1478–1488. doi: 10.1002/jnr.21272
Ciccocioppo, R., Cippitelli, A., Econo-
midou, D., Fedeli, A., and Massi,
M. (2004). Nociceptin/orphanin
FQ acts as a functional antago-
nist of corticotropin-releasing fac-
tor to inhibit its anorectic effect.
Physiol. Behav. 82, 63–68. doi:
10.1016/j.physbeh.2004.04.035
Ciccocioppo, R., Fedeli, A., Economi-
dou, D., Policani, F., Weiss, F., and
Massi, M. (2003). The bed nucleus
is a neuroanatomical substrate for
the anorectic effect of corticotropin-
releasing factor and for its reversal by
nociceptin/orphanin FQ. J. Neurosci.
23, 9445–9451.
Cruz, M. T., Herman, M. A., Kallupi,
M., and Roberto, M. (2012). Noci-
ceptin/orphanin FQ blockade of
corticotropin-releasing factor-
induced gamma-aminobutyric
acid release in central amygdala is
enhanced after chronic ethanol expo-
sure. Biol. Psychiatry 71, 666–676.
doi: 10.1016/j.biopsych.2011.10.032
Dantzer, R., O’Connor, J. C., Freund,
G. G., Johnson, R. W., and Kelley,
K. W. (2008). From inﬂammation to
sickness and depression: when the
immune system subjugates the brain.
Nat. Rev. Neurosci. 9, 46–56. doi:
10.1038/nrn2297
Dawe, K. L.,Wakerley, J. B., and Fulford,
A. J. (2010). Nociceptin/orphanin
FQ and the regulation of neuronal
excitability in the rat bed nucleus of
the stria terminalis: interaction with
glucocorticoids. Stress 13, 516–527.
Del Giudice, M. R., Borioni, A., Bas-
tanzio, G., Sbraccia, M., Mustazza,
C., and Sestili, I. (2011). Syn-
thesis and pharmacological evalua-
tion of bivalent antagonists of the
nociceptin opioid receptor. Eur. J.
Med. Chem. 46, 1207–1221. doi:
10.1016/j.ejmech.2011.01.040
Delaney, G., Dawe, K. L., Hogan,
R., Hunjan, T., Roper, J., Hazell,
G., et al. (2012). Role of noci-
ceptin/orphanin FQ and NOP recep-
tors in the response to acute and
repeated restraint stress in rats. J.
Neuroendocrinol. 24, 1527–1541. doi:
10.1111/j.1365-2826.2012.02361.x
Depner, U. B., Reinscheid, R. K.,
Takeshima, H., Brune, K., and
Zeilhofer, H. U. (2003). Nor-
mal sensitivity to acute pain, but
increased inﬂammatory hyperalge-
sia in mice lacking the nociceptin
precursor polypeptide or the noci-
ceptin receptor. Eur. J. Neurosci.
17, 2381–2387. doi: 10.1046/j.1460-
9568.2003.02676.x
Devine, D. P., Hoversten, M. T.,
Ueda, Y., and Akil, H. (2003).
Nociceptin/orphanin FQ content is
decreased in forebrain neurones dur-
ing acute stress. J. Neuroendocrinol.
15, 69–74. doi: 10.1046/j.1365-
2826.2003.00868.x
Devine, D. P., Taylor, L., Rein-
scheid, R. K., Monsma, F. J. Jr.,
Civelli, O., and Akil, H. (1996).
Rats rapidly develop tolerance to
the locomotor-inhibiting effects of
the novel neuropeptide orphanin FQ.
Neurochem. Res. 21, 1387–1396. doi:
10.1007/BF02532380
Devine, D. P., Watson, S. J., and
Akil,H. (2001). Nociceptin/orphanin
FQ regulates neuroendocrine func-
tion of the limbic-hypothalamic-
pituitary-adrenal axis. Neuroscience
102, 541–553. doi: 10.1016/S0306-
4522(00)00517-0
Duzzioni, M., Duarte, F. S., Leme,
L. R., Gavioli, E. C. and De Lima,
T. C. (2011) Anxiolytic-like effect
of central administration of NOP
receptor antagonist UFP-101 in rats
submitted to the elevated T-maze.
Behav. Brain Res. 222, 206–211. doi:
10.1016/j.bbr.2011.03.056
Easten, K. H., Harry, R. A., Pur-
cell, W. M., and McLeod, J. D.
(2009). Nociceptin-induced mod-
ulation of human T cell func-
tion. Peptides 30, 926–934. doi:
10.1016/j.peptides.2009.01.021
Eschenroeder, A. C., Vestal-Laborde,
A. A., Sanchez, E. S., Robin-
son, S. E., and Sato-Bigbee, C.
(2012). Oligodendrocyte responses
to buprenorphine uncover novel and
opposing roles of mu-opioid- and
nociceptin/orphanin FQ receptors
in cell development: implications
for drug addiction treatment during
pregnancy. Glia 60, 125–136. doi:
10.1002/glia.21253
Feder, A., Nestler, E. J., and Char-
ney, D. S. (2009). Psychobiology and
molecular genetics of resilience. Nat.
Rev. Neurosci. 10, 446–457. doi:
10.1038/nrn2649
Fernandez, F., Misilmeri, M. A.,
Felger, J. C., and Devine, D.
P. (2004). Nociceptin/orphanin FQ
increases anxiety-related behavior
and circulating levels of corticos-
terone during neophobic tests of anx-
iety. Neuropsychopharmacology 29,
59–71. doi: 10.1038/sj.npp.1300308
Finley, M. J., Happel, C. M.,
Kaminsky, D. E., and Rogers,
T. J. (2008). Opioid and noci-
ceptin receptors regulate cytokine
and cytokine receptor expression.
Cell. Immunol. 252, 146–154. doi:
10.1016/j.cellimm.2007.09.008
Fiset, M. E., Gilbert, C., Poubelle, P. E.,
and Pouliot, M. (2003). Human neu-
trophils as a source of nociceptin: a
novel link between pain and inﬂam-
mation. Biochemistry 42, 10498–
10505. doi: 10.1021/bi0300635
Florin, S., Suaudeau, C., Meunier,
J. C., and Costentin, J. (1996).
Nociceptin stimulates locomotion
and exploratory behaviour in mice.
Eur. J. Pharmacol. 317, 9–13. doi:
10.1016/S0014-2999(96)00707-8
Frank, M. G., Baratta, M. V., Sprunger,
D. B., Watkins, L. R., and Maier,
S. F. (2007). Microglia serve as a
neuroimmune substrate for stress-
induced potentiation of CNS pro-
inﬂammatory cytokine responses.
Brain Behav. Immun. 21, 47–59. doi:
10.1016/j.bbi.2006.03.005
Fu, X., Wang, Y. Q., Wang,
J., Yu, J., and Wu, G. C.
(2007a). Changes in expression
of nociceptin/orphanin FQ and its
receptor in spinal dorsal horn dur-
ing electroacupuncture treatment for
peripheral inﬂammatory pain in
rats. Peptides 28, 1220–1228. doi:
10.1016/j.peptides.2007.03.022
Fu, X., Zhu, Z. H., Wang, Y.
Q., and Wu, G. C. (2007b).
Regulation of proinﬂammatory
cytokines gene expression by noci-
ceptin/orphanin FQ in the spinal
cord and the cultured astrocytes.
Neuroscience 144, 275–285. doi:
10.1016/j.neuroscience.2006.09.016
Fu, X., Wang, Y. Q., and Wu,
G. C. (2006). Involvement of
nociceptin/orphanin FQ and its
receptor in electroacupuncture-
produced anti-hyperalgesia in rats
with peripheral inﬂammation.
Brain Res. 1078, 212–218. doi:
10.1016/j.brainres.2006.01.026
Fukuda, K., Kato, S., Mori, K., Nishi,
M., Takeshima, H., Iwabe, N., et al.
(1994). cDNA cloning and regional
distribution of a novel member of
the opioid receptor family. FEBS
Lett. 343, 42–46. doi: 10.1016/0014-
5793(94)80603-9
Gavioli, E. C., Rae, G. A., Calo,
G., Guerrini, R., and De Lima,
T. C. (2002). Central injections of
nocistatin or its C-terminal hexapep-
tide exert anxiogenic-like effect on
behaviour of mice in the plus-maze
test. Br. J. Pharmacol. 136, 764–772.
doi: 10.1038/sj.bjp.0704739
Gavioli, E. C., Rizzi, A., Marzola, G.,
Zucchini, S., Regoli, D., and Calo,
G. (2007). Altered anxiety-related
behavior in nociceptin/orphanin
FQ receptor gene knockout mice.
Peptides 28, 1229–1239. doi:
10.1016/j.peptides.2007.04.012
Gibb, J., Hayley, S., Gandhi, R., Poul-
ter, M. O., and Anisman, H. (2008).
Synergistic and additive actions of
a psychosocial stressor and endo-
toxin challenge: circulating and brain
cytokines, plasma corticosterone and
behavioral changes in mice. Brain
Behav. Immun. 22, 573–589. doi:
10.1016/j.bbi.2007.12.001
Gibb, J., Hayley, S., Poulter, M. O.,
and Anisman, H. (2011). Effects
of stressors and immune activat-
ing agents on peripheral and cen-
tral cytokines in mouse strains that
differ in stressor responsivity. Brain
Behav. Immun. 25, 468–482. doi:
10.1016/j.bbi.2010.11.008
Goeldner, C., Spooren, W., Wich-
mann, J., and Prinssen, E. P.
(2012). Further characterization of
the prototypical nociceptin/orphanin
FQ peptide receptor agonist Ro 64-
6198 in rodent models of conﬂict
anxiety and despair. Psychopharma-
cology (Berl.) 222, 203–214. doi:
10.1007/s00213-012-2636-x
Goldfarb, Y., Reinscheid, R. K., and
Kusnecov, A. W. (2006). Orphanin
FQ/nociceptin interactions with the
immune system in vivo: gene expres-
sion changes in lymphoid organs and
regulation of the cytokine response
to staphylococcal enterotoxin A. J.
Neuroimmunol. 176, 76–85. doi:
10.1016/j.jneuroim.2006.04.008
Gompf, H. S., Moldavan, M. G.,
Irwin, R. P., and Allen, C. N.
(2005). Nociceptin/orphanin FQ
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 173 | 15
“fncel-07-00173” — 2013/10/4 — 21:26 — page 16 — #16
Mallimo and Kusnecov Orphanin FQ/nociceptin, stress, neuroinﬂammation
(N/OFQ) inhibits excitatory and
inhibitory synaptic signaling in
the suprachiasmatic nucleus (SCN).
Neuroscience 132, 955–965. doi:
10.1016/j.neuroscience.2004.11.057
Graeber, M. B., Li, W., and
Rodriguez, M. L. (2011). Role
of microglia in CNS inﬂammation.
FEBS Lett. 585, 3798–3805. doi:
10.1016/j.febslet.2011.08.033
Green, M. K., Barbieri, E. V., Brown,
B. D., Chen, K. W., and Devine,
D. P. (2007). Roles of the bed
nucleus of stria terminalis and of
the amygdala in N/OFQ-mediated
anxiety and HPA axis activation.
Neuropeptides 41, 399–410. doi:
10.1016/j.npep.2007.09.002
Green, M. K., and Devine, D. P.
(2009). Nociceptin/orphanin FQ and
NOP receptor gene regulation after
acute or repeated social defeat stress.
Neuropeptides 43, 507–514. doi:
10.1016/j.npep.2009.08.003
Halford, W. P., Gebhardt, B. M., and
Carr, D. J. (1995). Functional role
and sequence analysis of a lym-
phocyte orphan opioid receptor. J.
Neuroimmunol. 59, 91–101. doi:
10.1016/0165-5728(95)00030-6
Hawes, B. E., Graziano, M. P., and Lam-
bert, D. G. (2000). Cellular actions
of nociceptin: transduction mech-
anisms. Peptides 21, 961–967. doi:
10.1016/S0196-9781(00)00232-1
Heneka, M. T., Nadrigny, F., Regen,
T., Martinez-Hernandez, A.,
Dumitrescu-Ozimek, L., Terwel,
D., et al. (2010). Locus ceruleus con-
trols Alzheimer’s disease pathology
by modulating microglial functions
through norepinephrine. Proc. Natl.
Acad. Sci. U.S.A. 107, 6058–6063.
doi: 10.1073/pnas.0909586107
Herman, J. P., McKlveen, J. M.,
Solomon, M. B., Carvalho-Netto, E.,
and Myers, B. (2012). Neural regula-
tion of the stress response: glucocor-
ticoid feedback mechanisms. Braz. J.
Med. Biol. Res. 45, 292–298. doi:
10.1590/S0100-879X2012007500041
Hinwood, M., Morandini, J., Day, T. A.,
and Walker, F. R. (2012). Evidence
that microglia mediate the neurobio-
logical effects of chronic psycholog-
ical stress on the medial prefrontal
cortex. Cereb. Cortex 22, 1442–1454.
doi: 10.1093/cercor/bhr229
Ikeda, K., Watanabe, M., Ichikawa,
T., Kobayashi, T., Yano, R., and
Kumanishi, T. (1998). Distribution
of prepro-nociceptin/orphanin FQ
mRNA and its receptor mRNA in
developing and adult mouse central
nervous systems. J. Comp. Neu-
rol. 399, 139–151. doi: 10.1002/
(SICI)1096-9861(19980914)399:1<
139::AID-CNE11>3.0.CO;2-C
Itoh, K., Konya, H., Takai, E., Masuda,
H., and Nagai, K. (1999). Modi-
ﬁcation of acetylcholine release by
nociceptin in conscious rat stria-
tum. Brain Res. 845, 242–245. doi:
10.1016/S0006-8993(99)01954-X
Jankord, R., and Herman, J. P. (2008).
Limbic regulation of hypothalamo-
pituitary-adrenocortical function
during acute and chronic stress. Ann.
N. Y. Acad. Sci. 1148, 64–73. doi:
10.1196/annals.1410.012
Jenck, F., Moreau, J. L., Martin, J.
R., Kilpatrick, G. J., Reinscheid,
R. K., Monsma, F. J. Jr., et al.
(1997). Orphanin FQ acts as an
anxiolytic to attenuate behavioral
responses to stress. Proc. Natl. Acad.
Sci. U.S.A. 94, 14854–14858. doi:
10.1073/pnas.94.26.14854
Jenck, F., Wichmann, J., Dautzenberg,
F. M., Moreau, J. L., Ouagazzal,
A. M., Martin, J. R., et al. (2000).
A synthetic agonist at the orphanin
FQ/nociceptin receptor ORL1: anx-
iolytic proﬁle in the rat. Proc. Natl.
Acad. Sci. U.S.A. 97, 4938–4943. doi:
10.1073/pnas.090514397
Kamei, J., Matsunawa, Y., Miy-
ata, S., Tanaka, S., and Saitoh,
A. (2004). Effects of nociceptin
on the exploratory behavior of
mice in the hole-board test. Eur.
J. Pharmacol. 489, 77–87. doi:
10.1016/j.ejphar.2003.12.020
Kato, S., Tsuzuki, Y., Hokari, R.,
Okada, Y., Miyazaki, J., Mat-
suzaki, K., et al. (2005). Role of
nociceptin/orphanin FQ (Noc/oFQ)
in murine experimental colitis. J.
Neuroimmunol. 161, 21–28. doi:
10.1016/j.jneuroim.2004.12.006
Kawashima, N., Fugate, J., and Kus-
necov, A. W. (2002). Immunological
challenge modulates brain orphanin
FQ/nociceptin and nociceptive
behavior. Brain Res. 949, 71–78. doi:
10.1016/S0006-8993(02)02966-9
Kettenmann, H., Hanisch, U. K., Noda,
M., andVerkhratsky, A. (2011). Phys-
iology of microglia. Physiol. Rev.
91, 461–553. doi: 10.1152/phys-
rev.00011.2010
Koob, G. F. (2008). A role for
brain stress systems in addic-
tion. Neuron 59, 11–34. doi:
10.1016/j.neuron.2008.06.012
Koster, A., Montkowski, A., Schulz,
S., Stube, E. M., Knaudt, K.,
Jenck, F., et al. (1999). Tar-
geted disruption of the orphanin
FQ/nociceptin gene increases stress
susceptibility and impairs stress
adaptation in mice. Proc. Natl. Acad.
Sci. U.S.A. 96, 10444–10449. doi:
10.1073/pnas.96.18.10444
Kuzmin, A., Madjid, N., Johansson,
B., Terenius, L., and Ogren, S. O.
(2009). The nociceptin system and
hippocampal cognition in mice: a
pharmacological and genetic analy-
sis. Brain Res. 1305(Suppl.), S7–S19.
doi: 10.1016/j.brainres.2009.09.075
Lachowicz, J. E., Shen, Y., Monsma, F. J.
Jr., and Sibley, D. R. (1995). Molec-
ular cloning of a novel G protein-
coupled receptor related to the
opiate receptor family. J. Neurochem.
64, 34–40. doi: 10.1046/j.1471-
4159.1995.64010034.x
Leggett, J. D., Dawe, K. L., Jessop, D. S.,
and Fulford, A. J. (2009a). Endoge-
nous nociceptin/orphanin FQ system
involvement in hypothalamic-
pituitary-adrenal axis responses:
relevance tomodels of inﬂammation.
J. Neuroendocrinol. 21, 888–897. doi:
10.1111/j.1365-2826.2009.01912.x
Leggett, J. D., Dawe, K. L., Jessop, D. S.,
and Fulford, A. J. (2009b). Endoge-
nous nociceptin/orphanin FQ system
involvement in HPA axis responses:
relevance tomodels of inﬂammation.
J. Neuroendocrinol. 21, 888–897. doi:
10.1111/j.1365-2826.2009.01912.x
Leggett, J. D., Harbuz, M. S., Jes-
sop, D. S., and Fulford, A. J. (2006).
The nociceptin receptor antagonist
[Nphe1,Arg14,Lys15]nociceptin/
orphanin FQ-NH2 blocks the stimu-
latory effects of nociceptin/orphanin
FQ on the HPA axis in rats.
Neuroscience 141, 2051–2057. doi:
10.1016/j.neuroscience.2006.05.036
Leggett, J. D., Jessop, D. S., and
Fulford, A. J. (2007). The noci-
ceptin/orphanin FQ antagonist
UFP-101 differentially modu-
lates the glucocorticoid response
to restraint stress in rats dur-
ing the peak and nadir phases
of the hypothalamo-pituitary-
adrenal axis circadian rhythm.
Neuroscience 147, 757–764. doi:
10.1016/j.neuroscience.2007.04.010
Mahmoud, S., Margas, W., Trapella, C.,
Calo, G., and Ruiz-Velasco, V. (2010).
Modulation of silent and constitu-
tively active nociceptin/orphanin FQ
receptors by potent receptor antago-
nists andNa+ ions in rat sympathetic
neurons. Mol. Pharmacol. 77, 804–
817. doi: 10.1124/mol.109.062208
Mallimo, E. M., Ansonoff, M. A., Pintar,
J. E., and Kusnecov, A. W. (2010).
Role of opioid receptor like-1 recep-
tor in modulation of endocrine,
immunological, and behavioral
responses to the T-cell superanti-
gen staphylococcal enterotoxin A.
J. Neuroimmunol. 218, 48–56. doi:
10.1016/j.jneuroim.2009.10.014
Mamiya, T., Noda, Y., Nishi, M.,
Takeshima, H., and Nabeshima,
T. (1998). Enhancement of spatial
attention in nociceptin/orphanin FQ
receptor-knockout mice. Brain Res.
783, 236–240. doi: 10.1016/S0006-
8993(97)01406-6
Matta, S. G., Fu, Y., Valentine, J. D., and
Sharp, B. M. (1998). Response of the
hypothalamo-pituitary-adrenal axis
to nicotine. Psychoneuroendocrinol-
ogy 23, 103–113. doi: 10.1016/S0306-
4530(97)00079-6
Meis, S., and Pape, H. C. (2001).
Control of glutamate and GABA
release by nociceptin/orphanin FQ in
the rat lateral amygdala. J. Physiol.
532, 701–712. doi: 10.1111/j.1469-
7793.2001.0701e.x
Meunier, J. C., Mollereau, C., Toll,
L., Suaudeau, C., Moisand, C.,
Alvinerie, P., et al. (1995). Isola-
tion and structure of the endogenous
agonist of opioid receptor-like ORL1
receptor. Nature 377, 532–535. doi:
10.1038/377532a0
Miller, T. R., and Fulford, A.
J. (2007). Regulation of noci-
ceptin/orphaninFQ secretion by
immune cells and functional
modulation of interleukin-2.
Peptides 28, 2243–2252. doi:
10.1016/j.peptides.2007.09.004
Mogil, J. S., and Pasternak, G.
W. (2001). The molecular and
behavioral pharmacology of the
orphaninFQ/nociceptin peptide and
receptor family. Pharmacol. Rev. 53,
381–415.
Mollereau, C., Parmentier, M.,
Mailleux, P., Butour, J. L., Moisand,
C., Chalon, P., et al. (1994).
ORL1, a novel member of the
opioid receptor family. Cloning,
functional expression and localiza-
tion. FEBS Lett. 341, 33–38. doi:
10.1016/0014-5793(94)80235-1
Mollereau, C., Simons, M. J., Soularue,
P., Liners, F., Vassart, G., Meunier,
J. C., et al. (1996). Structure, tissue
distribution, and chromosomal local-
ization of the prepronociceptin gene.
Proc. Natl. Acad. Sci. U.S.A. 93, 8666–
8670. doi: 10.1073/pnas.93.16.8666
Nabeshima,T.,Noda,Y., andMamiya, T.
(1999). The role of nociceptin in cog-
nition. Brain Res. 848, 167–173. doi:
10.1016/S0006-8993(99)01906-X
Nativio, P., Pascale, E., Maffei, A.,
Scaccianoce, S., and Passarelli, F.
(2012). Effect of stress on hip-
pocampal nociceptin expression in
the rat. Stress 15, 378–384. doi:
10.3109/10253890.2011.627071
Neal, C. R. Jr., Mansour, A., Rein-
scheid, R., Nothacker, H. P., Civelli,
O., Akil, H., et al. (1999a). Opi-
oid receptor-like (ORL1) receptor
distribution in the rat central ner-
vous system: comparison of ORL1
receptor mRNA expression with
(125)I-[(14)Tyr]-orphanin FQ
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 173 | 16
“fncel-07-00173” — 2013/10/4 — 21:26 — page 17 — #17
Mallimo and Kusnecov Orphanin FQ/nociceptin, stress, neuroinﬂammation
binding. J. Comp. Neurol. 412,
563–605. doi: 10.1002/(SICI)1096-
9861(19991004)412:4<563::AID-
CNE2>3.0.CO;2-Z
Neal, C. R. Jr., Mansour, A., Rein-
scheid, R., Nothacker, H. P., Civelli,
O., and Watson, S. J. Jr. (1999b).
Localization of orphanin FQ (noci-
ceptin) peptide and messenger
RNA in the central nervous system
of the rat. J. Comp. Neurol. 406,
503–547. doi: 10.1002/(SICI)1096-
9861(19990419)406:4<503::AID-
CNE7>3.0.CO;2-P
Nicholson, J. R., Akil, H., and Watson,
S. J. (2002). Orphanin FQ-induced
hyperphagia is mediated by corti-
costerone and central glucocorticoid
receptors.Neuroscience 115, 637–643.
doi: 10.1016/S0306-4522(02)00290-
7
Noda,Y.,Mamiya, T.,Manabe, T., Nishi,
M., Takeshima, H., and Nabeshima,
T. (2000). Role of nociceptin systems
in learning and memory. Peptides
21, 1063–1069. doi: 10.1016/S0196-
9781(00)00244-8
Nothacker, H. P., Reinscheid, R. K.,
Mansour, A., Henningsen, R. A.,
Ardati, A., Monsma, F. J. Jr., et al.
(1996). Primary structure and tis-
sue distribution of the orphanin
FQ precursor. Proc. Natl. Acad.
Sci. U.S.A. 93, 8677–8682. doi:
10.1073/pnas.93.16.8677
Okuda-Ashitaka, E., Minami, T.,
Tachibana, S., Yoshihara, Y., Nishi-
uchi, Y., Kimura, T., et al. (1998).
Nocistatin, a peptide that blocks
nociceptin action in pain transmis-
sion. Nature 392, 286–289. doi:
10.1038/32660
Olszewski, P. K., Billington, C. J., and
Levine,A. S. (2000). Fos expression in
feeding-related brain areas following
intracerebroventricular administra-
tionof orphaninFQ in rats. BrainRes.
855, 171–175. doi: 10.1016/S0006-
8993(99)02239-8
Ouagazzal, A. M., Moreau, J. L.,
Pauly-Evers, M., and Jenck, F.
(2003). Impact of environmental
housing conditions on the emo-
tional responses of mice deﬁcient
for nociceptin/orphanin FQ peptide
precursor gene. Behav. Brain Res.
144, 111–117. doi: 10.1016/S0166-
4328(03)00066-4
Pampusch, M. S., Serie, J. R., Osinski,
M. A., Seybold, V. S., Murtaugh, M.
P., and Brown, D. R. (2000). Expres-
sion of nociceptin/OFQ receptor and
prepro-nociceptin/OFQ in lymphoid
tissues. Peptides 21, 1865–1870. doi:
10.1016/S0196-9781(00)00332-6
Peluso, J., LaForge, K. S., Matthes,
H. W., Kreek, M. J., Kieffer, B.
L., and Gaveriaux-Ruff, C. (1998).
Distribution of nociceptin/orphanin
FQ receptor transcript in human cen-
tral nervous system and immune
cells. J. Neuroimmunol. 81, 184–
192. doi: 10.1016/S0165-5728(97)
00178-1
Perez Nievas, B. G., Hammerschmidt,
T., Kummer, M. P., Terwel, D.,
Leza, J. C., and Heneka, M. T.
(2011). Restraint stress increases neu-
roinﬂammation independently of
amyloid beta levels in amyloid
precursor protein/PS1 transgenic
mice. J. Neurochem. 116, 43–52. doi:
10.1111/j.1471-4159.2010.07083.x
Petrella, C., Giuli, C., Broccardo,
M., Eutamene, H., Cartier, C.,
Leveque, M., et al. (2013). Pro-
tective and worsening peripheral
nociceptin/orphanin FQ receptor-
mediated effect in a rat model
of experimental colitis. Phar-
macol. Res. 70, 72–79. doi:
10.1016/j.phrs.2013.01.004
Polidori, C., de Caro, G., and
Massi, M. (2000). The hyperphagic
effect of nociceptin/orphanin FQ in
rats. Peptides 21, 1051–1062. doi:
10.1016/S0196-9781(00)00243-6
Pomonis, J. D., Billington, C. J., and
Levine, A. S. (1996). Orphanin
FQ, agonist of orphan opioid recep-
tor ORL1, stimulates feeding in
rats. Neuroreport 8, 369–371. doi:
10.1097/00001756-199612200-00072
Prendergast, C. T., and Anderton, S. M.
(2009). Immune cell entry to cen-
tral nervous system – current under-
standing and prospective therapeutic
targets. Endocr. Metab. Immune Dis-
ord. Drug Targets 9, 315–327. doi:
10.2174/187153009789839219
Ransohoff, R. M., and Perry, V.
H. (2009). Microglial physiology:
unique stimuli, specialized responses.
Annu. Rev. Immunol. 27, 119–
145. doi: 10.1146/annurev.immunol.
021908.132528
Reinscheid, R. K., Ardati, A., Mon-
sma, F. J. Jr., and Civelli, O.
(1996). Structure-activity relation-
ship studies on the novel neu-
ropeptide orphanin FQ. J. Biol.
Chem. 271, 14163–14168. doi:
10.1074/jbc.271.24.14163
Reinscheid, R. K., Nothacker, H., and
Civelli, O. (2000). The orphanin
FQ/nociceptin gene: structure, tissue
distribution of expression and func-
tional implications obtained from
knockout mice. Peptides 21, 901–
906. doi: 10.1016/S0196-9781(00)
00226-6
Reinscheid, R. K., Nothacker, H.
P., Bourson, A., Ardati, A.,
Henningsen, R. A., Bunzow, J.
R., et al. (1995). Orphanin FQ:
a neuropeptide that activates an
opioidlike G protein-coupled recep-
tor. Science 270, 792–794. doi:
10.1126/science.270.5237.792
Rhodes, M. E., O’Toole, S. M., Czam-
bel, R. K., and Rubin, R. T.
(2001).Male-female differences in rat
hypothalamic-pituitary-adrenal axis
responses to nicotine stimulation.
Brain Res. Bull. 54, 681–688. doi:
10.1016/S0361-9230(01)00488-9
Rizzi, A., Bigoni, R., Marzola, G.,
Guerrini, R., Salvadori, S., Regoli,
D., et al. (2001). Characterization
of the locomotor activity-inhibiting
effect of nociceptin/orphanin FQ in
mice. Naunyn Schmiedebergs Arch.
Pharmacol. 363, 161–165. doi:
10.1007/s002100000358
Rizzi, A., Molinari, S., Marti,
M., Marzola, G., and Calo, G.
(2011). Nociceptin/orphanin
FQ receptor knockout rats: in
vitro and in vivo studies. Neu-
ropharmacology 60, 572–579. doi:
10.1016/j.neuropharm.2010.12.010
Roberto, M., and Siggins, G. R. (2006).
Nociceptin/orphanin FQ presynapti-
cally decreases GABAergic transmis-
sion and blocks the ethanol-induced
increase of GABA release in cen-
tral amygdala. Proc. Natl. Acad.
Sci. U.S.A. 103, 9715–9720. doi:
10.1073/pnas.0601899103
Rodgers, R. J. (1997). Animal mod-
els of ‘anxiety’: where next? Behav.
Pharmacol. 8, 477–496; discussion
497–504. doi: 10.1097/00008877-
199711000-00003
Rodi, D., Zucchini, S., Simonato, M.,
Cifani, C., Massi, M., and Poli-
dori, C. (2008). Functional antag-
onism between nociceptin/orphanin
FQ (N/OFQ) and corticotropin-
releasing factor (CRF) in the rat
brain: evidence for involvement of
the bed nucleus of the stria ter-
minalis. Psychopharmacology (Berl.)
196, 523–531. doi: 10.1007/s00213-
007-0985-7
Rossi, G. C., Perlmutter, M., Leven-
thal, L., Talatti, A., and Pasternak, G.
W. (1998). Orphanin FQ/nociceptin
analgesia in the rat. Brain Res.
792, 327–330. doi: 10.1016/S0006-
8993(97)01490-X
Rossi-George, A., Urbach, D., Colas,
D., Goldfarb, Y., and Kusnecov, A.
W. (2005). Neuronal, endocrine,
and anorexic responses to the
T-cell superantigen staphylococ-
cal enterotoxin A: dependence
on tumor necrosis factor-alpha.
J. Neurosci. 25, 5314–5322. doi:
10.1523/JNEUROSCI.0687-05.2005
Sakoori, K., and Murphy, N. P.
(2010). Reduced degeneration of
dopaminergic terminals and accentu-
ated astrocyte activation by high dose
methamphetamine administration in
nociceptin receptor knock out mice.
Neurosci. Lett. 469, 309–313. doi:
10.1016/j.neulet.2009.12.014
Santello, M., Cali, C., and Bezzi, P.
(2012). Gliotransmission and the tri-
partite synapse. Adv. Exp. Med. Biol.
970, 307–331. doi: 10.1007/978-3-
7091-0932-8_14
Sapolsky, R. M., McEwen, B. S.,
and Rainbow, T. C. (1983).
Quantitative autoradiography of
[3H]corticosterone receptors in rat
brain. Brain Res. 271, 331–334. doi:
10.1016/0006-8993(83)90295-0
Schlicker, E., and Morari, M. (2000).
Nociceptin/orphanin FQ and neu-
rotransmitter release in the central
nervous system. Peptides 21, 1023–
1029. doi: 10.1016/S0196-9781(00)
00233-3
Serhan, C. N., Fierro, I. M., Chiang,
N., and Pouliot, M. (2001). Cut-
ting edge: nociceptin stimulates neu-
trophil chemotaxis and recruitment:
inhibition by aspirin-triggered-15-
epi-lipoxin A4. J. Immunol. 166,
3650–3654.
Serrano-Gomez, A., Thompson, J. P.,
and Lambert, D. G. (2011). Noci-
ceptin/orphanin FQ in inﬂammation
and sepsis. Br. J. Anaesth. 106, 6–12.
doi: 10.1093/bja/aeq337
Sestili, I., Borioni, A., Mustazza,
C., Rodomonte, A., Turchetto,
L., Sbraccia, M., et al. (2004). A
new synthetic approach of N-(4-
amino-2-methylquinolin-6-yl)-2-
(4-ethylphenoxymethyl)benzamide
(JTC-801) and its analogues and their
pharmacological evaluation as noci-
ceptin receptor (NOP) antagonists.
Eur. J. Med. Chem. 39, 1047–1057.
doi: 10.1016/j.ejmech.2004.09.009
Spulber, S., and Schultzberg, M. (2010).
Connection between inﬂammatory
processes and transmittor function-
modulatory effects of interleukin-1.
Prog. Neurobiol. 90, 256–262. doi:
10.1016/j.pneurobio.2009.10.015
Stipursky, J., Romao, L., Tortelli, V.,
Neto, V. M., and Gomes, F. C. (2011).
Neuron-glia signaling: Implications
for astrocyte differentiation and
synapse formation. Life Sci. 89, 524–
531. doi: 10.1016/j.lfs.2011.04.005
Stratford, T. R., Holahan, M. R.,
and Kelley, A. E. (1997). Injec-
tions of nociceptin into nucleus
accumbens shell or ventromedial
hypothalamic nucleus increase food
intake. Neuroreport 8, 423–426. doi:
10.1097/00001756-199701200-00009
Sugama, S., Fujita, M., Hashimoto,
M., and Conti, B. (2007). Stress
induced morphological microglial
activation in the rodent brain:
involvement of interleukin-18.
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 173 | 17
“fncel-07-00173” — 2013/10/4 — 21:26 — page 18 — #18
Mallimo and Kusnecov Orphanin FQ/nociceptin, stress, neuroinﬂammation
Neuroscience 146, 1388–1399. doi:
10.1016/j.neuroscience.2007.02.043
Sugama, S., Takenouchi, T., Fujita,
M., Conti, B., and Hashimoto, M.
(2009). Differential microglial acti-
vation between acute stress and
lipopolysaccharide treatment. J.
Neuroimmunol. 207, 24–31. doi:
10.1016/j.jneuroim.2008.11.007
Sugama, S., Takenouchi, T., Sekiyama,
K., Kitani, H., and Hashimoto, M.
(2011). Immunological responses
of astroglia in the rat brain
under acute stress: interleukin
1 beta co-localized in astroglia.
Neuroscience 192, 429–437. doi:
10.1016/j.neuroscience.2011.06.051
Sugino, T., Shimazoe, T., Ikeda, M.,
and Watanabe, S. (2006). Role
of nociceptin and opioid recep-
tor like 1 on entrainment function
in the rat suprachiasmatic nucleus.
Neuroscience 137, 537–544. doi:
10.1016/j.neuroscience.2005.08.085
Takayama, N., and Ueda, H. (2005).
Morphine-induced overexpression
of prepro-nociceptin/orphanin
FQ in cultured astrocytes.
Peptides 26, 2513–2517. doi:
10.1016/j.peptides.2005.05.005
Trombella, S., Vergura, R., Falzarano, S.,
Guerrini, R., Calo, G., and Spisani,
S. (2005). Nociceptin/orphanin FQ
stimulates human monocyte chemo-
taxis via NOP receptor activa-
tion. Peptides 26, 1497–1502. doi:
10.1016/j.peptides.2005.03.015
Uchiyama, H., Yamaguchi, T., Toda,
A., Hiranita, T., Watanabe, S.,
and Eyanagi, R. (2008). Involve-
ment of the GABA/benzodiazepine
receptor in the axiolytic-like effect
of nociceptin/orphanin FQ. Eur.
J. Pharmacol. 590, 185–189. doi:
10.1016/j.ejphar.2008.05.031
Uezu, K., Sano, A., Sei, H.,
Toida, K., Houtani, T., Sugimoto,
T., et al. (2005). Enhanced hip-
pocampal acetylcholine release in
nociceptin-receptor knockout mice.
Brain Res. 1050, 118–123. doi:
10.1016/j.brainres.2005.05.044
Ulrich-Lai, Y. M., and Herman, J.
P. (2009). Neural regulation of
endocrine and autonomic stress
responses. Nat. Rev. Neurosci. 10,
397–409. doi: 10.1038/nrn2647
Varty, G. B., Hyde, L. A., Hodgson,
R. A., Lu, S. X., McCool, M. F.,
Kazdoba, T. M., et al. (2005). Charac-
terization of the nociceptin receptor
(ORL-1) agonist, Ro64-6198, in tests
of anxiety across multiple species.
Psychopharmacology (Berl.) 182,
132–143. doi: 10.1007/s00213-005-
0041-4
Vitale,G.,Arletti, R., Ruggieri,V.,Cifani,
C., and Massi, M. (2006). Anxiolytic-
like effects of nociceptin/orphanin
FQ in the elevated plus maze and
in the conditioned defensive bury-
ing test in rats. Peptides 27, 2193–
2200. doi: 10.1016/j.peptides.2006.
04.003
Wager-Smith, K., and Markou, A.
(2011). Depression: a repair response
to stress-induced neuronal micro-
damage that can grade into a chronic
neuroinﬂammatory condition? Neu-
rosci. Biobehav. Rev. 35, 742–
764. doi: 10.1016/j.neubiorev.2010.
09.010
Waits, P. S., Purcell, W. M., Fulford,
A. J., and McLeod, J. D. (2004).
Nociceptin/orphanin FQ modulates
human T cell function in vitro. J.
Neuroimmunol. 149, 110–120. doi:
10.1016/j.jneuroim.2003.12.018
Wang, J. B., Johnson, P. S., Imai, Y.,
Persico, A. M., Ozenberger, B. A.,
Eppler, C. M., et al. (1994). cDNA
cloning of an orphan opiate recep-
tor gene family member and its splice
variant. FEBS Lett. 348, 75–79. doi:
10.1016/0014-5793(94)00557-5
Wick, M. J., Minnerath, S. R., Lin,
X., Elde, R., Law, P. Y., and Loh,
H. H. (1994). Isolation of a novel
cDNA encoding a putative mem-
brane receptor with high homol-
ogy to the cloned mu, delta, and
kappa opioid receptors. Brain Res.
Mol. Brain Res. 27, 37–44. doi:
10.1016/0169-328X(94)90181-3
Wohleb, E. S., Hanke, M. L.,
Corona, A. W., Powell, N. D.,
Stiner, L. M., Bailey, M. T.,
et al. (2011). beta-Adrenergic recep-
tor antagonism prevents anxiety-like
behavior and microglial reactivity
induced by repeated social defeat.
J. Neurosci. 31, 6277–6288. doi:
10.1523/JNEUROSCI.0450-11.2011
Zaveri, N. T. (2011). The noci-
ceptin/orphanin FQ receptor
(NOP) as a target for drug
abuse medications. Curr. Top.
Med. Chem 11, 1151–1156. doi:
10.2174/156802611795371341
Zhao, H., Huang, H. W.,Wu, G. C., and
Cao, X. D. (2002). Effect of orphanin
FQon interleukin-1betamRNA tran-
scripts in the rat CNS. Neuroscience
114, 1019–1031. doi: 10.1016/S0306-
4522(02)00233-6
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 18 May 2013; accepted: 14
September 2013; published online: 08
October 2013.
Citation: Mallimo EM and Kusnecov
AW (2013) The role of orphanin
FQ/nociceptin in neuroplasticity: rela-
tionship to stress, anxiety and neuroin-
ﬂammation. Front. Cell. Neurosci. 7:173.
doi: 10.3389/fncel.2013.00173
This article was submitted to the journal
Frontiers in Cellular Neuroscience
Copyright © 2013 Mallimo and Kus-
necov. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) or licensor are cred-
ited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use, dis-
tribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 173 | 18
